Details of the Drug

General Information of Drug (ID: DM7RJXL)

Drug Name
Imatinib
Synonyms
Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [2]
Choroidal neovascularization 9B76 Approved [2]
Chronic eosinophilic leukemia N.A. Approved [2]
Chronic myelogenous leukaemia 2A20.0 Approved [3]
Chronic myeloid leukaemia 2A20 Approved [4]
Dermatofibrosarcoma protuberans N.A. Approved [2]
Gastrointestinal stromal tumour 2B5B Approved [2]
Leukemia N.A. Approved [2]
Malignant peripheral nerve sheath tumor N.A. Approved [2]
Myeloproliferative neoplasm 2A20 Approved [2]
Pulmonary hypertension BB01 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Intestinal cancer 2C0Z Phase 3 [3]
Lung cancer 2C25.0 Phase 2 [3]
Idiopathic hypereosinophilic syndrome N.A. Investigative [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [6]
Scleroderma 4A42 Investigative [2]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [6]
Systemic mastocytosis 2A21.0 Investigative [7]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EA01: Imatinib
L01EA: BCR-ABL tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 493.6
Logarithm of the Partition Coefficient (xlogp) 3.5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [8]
Bioavailability
98% of drug becomes completely available to its intended biological destination(s) [9]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [10]
Elimination
5% of drug is excreted from urine in the unchanged form [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 hours [10]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.25863 micromolar/kg/day [11]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [10]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [10]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [8]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Chronic myeloid leukaemia Not Available LEP OT5Q7ODW [12]
Chemical Identifiers
Formula
C29H31N7O
IUPAC Name
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
InChIKey
KTUFNOKKBVMGRW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5291
ChEBI ID
CHEBI:45783
CAS Number
152459-95-5
UNII
BKJ8M8G5HI
DrugBank ID
DB00619
TTD ID
D0AZ3C
VARIDT ID
DR00032
INTEDE ID
DR0858
ACDINA ID
D00324
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [13]
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN Not Available [7]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [13]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [13]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [15]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [17]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [17]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [18]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [19]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [20]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [21]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [23]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [24]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [25]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [20]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [26]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Gene/Protein Processing [27]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [28]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [28]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM) OT1QY9JM PFKAM_HUMAN Gene/Protein Processing [29]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [30]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Post-Translational Modifications [31]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Drug Response [32]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [33]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Drug Response [34]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 207 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -4.6085 -0.0423 -4.6331 69.4489
MEC1 CTRP2 5.4354 6.0411 5.3807 4.2482
JM1 GDSC1; CTRP2 4.8305 8.0954 3.8897 11.7081
EoL-1 GDSC1; CTRP2 -11.2023 -9.6795 -11.2023 99.8203
JURL-MK1 GDSC1; CTRP2 -3.2633 -0.5797 -3.2645 61.937
ALL-SIL GDSC1; CTRP2 -3.2279 -0.3647 -3.23 61.6749
KYO-1 CTRP2 -3.1366 -2.3761 -3.1366 61.1654
LAMA-84 GDSC1; CTRP2 -3.1262 -1.2818 -3.1262 61.0904
MY-M12 GDSC1 -3.1039 2.099 -3.8206 50.8938
NCO2 CTRP2 -3.0116 -0.7544 -3.0119 60.3128
MOLM-6 CTRP2 -2.8936 -0.1663 -2.8954 59.4904
MEG-01 GDSC1 -2.8633 0.2297 -3.0336 48.4801
EM-2 GDSC1; CTRP2 -2.8464 -0.0499 -2.8488 59.171
CML-T1 CTRP2 -2.1957 0.1151 -2.1965 54.8882
BV-173 GDSC1; CTRP2 -2.1299 1.4262 -2.1505 54.3703
K-562 GDSC1; CTRP2 -1.2967 3.5046 -1.4435 48.9758
KCL-22 GDSC1; CTRP2 -0.8678 2.5096 -0.9016 46.1106
Kasumi-1 GDSC1; CTRP2 -0.0946 3.7126 -0.1921 41.1594
Ku812 GDSC1; CTRP2 0.0349 2.2139 0.0302 40.0511
BE-13 GDSC1 0.799 13.8102 -5.5733 35.0027
SUP-B15 GDSC1; CTRP2 1.0985 11.8299 -1.5687 39.1322
Peer CTRP2 1.9097 6.0223 1.5381 28.8076
YT GDSC1 2.051 4.5176 0.0209 4.6375
Karpas-45 GDSC1 2.2269 4.3519 0.2024 2.9949
IM-9 GDSC1 2.2798 3.7597 0.4846 1.1732
EB2 GDSC1 2.3112 5.7504 -0.3915 6.9838
MC116 GDSC1; CTRP2 2.3229 4.8379 2.2375 25.0825
Ramos.2G6.4C10 GDSC1 2.3499 4.2405 0.3183 2.0347
DoHH2 GDSC1 2.3782 4.2931 0.3106 2.0374
P32/ISH GDSC1 2.3846 3.6466 0.5767 0.6171
BC-1 GDSC1 2.3951 4.8535 0.0742 3.5301
HH [Human lymphoma] GDSC1 2.5143 5.896 -0.3306 6.0712
Karpas-231 GDSC1 2.5333 3.9906 0.5082 0.7833
LC4-1 GDSC1 2.5518 9.9029 -2.2337 18.0634
Farage GDSC1 2.5847 4.1967 0.4503 1.0009
CTV-1 GDSC1 2.6087 4.1351 0.485 0.8175
KOPN-8 GDSC1 2.6159 4.5796 0.3101 1.696
BL-41 GDSC1 2.6455 3.9301 0.5775 0.4254
KY821 GDSC1 2.6471 4.5437 0.3399 1.4923
MLMA GDSC1 2.6589 4.9451 0.1782 2.403
MHH-PREB-1 GDSC1 2.6785 4.4276 0.4013 1.1403
BC-3 GDSC1 2.6823 4.205 0.4897 0.7327
Loucy GDSC1 2.7533 5.1502 0.1397 2.4891
TUR GDSC1 2.8628 4.4896 0.4575 0.7188
SCC-3 GDSC1 2.8653 4.1767 0.5733 0.3208
MN-60 GDSC1 2.8789 7.6143 -0.9031 9.1387
ME1 GDSC1 2.9142 4.4777 0.483 0.5841
EB1 CTRP2 2.9234 6.2153 2.5902 21.9603
Hs 445 GDSC1 2.9873 4.4038 0.5386 0.3611
REC-1 CTRP2 3.0005 5.9843 2.7387 21.1914
CTB-1 GDSC1 3.0382 5.8886 -0.0275 3.0548
ALL-PO GDSC1 3.0691 11.3633 -2.5749 18.3578
VAL GDSC1 3.0697 14.3861 -4.0562 24.4567
SU-DHL-16 GDSC1 3.1088 4.3904 0.5879 0.1936
RPMI-8866 GDSC1 3.115 4.8757 0.4165 0.6908
CESS GDSC1 3.148 4.667 0.5055 0.3782
GA-10 GDSC1; CTRP2 3.1665 6.0734 2.8957 20.1202
NKM-1 GDSC1 3.1745 8.5118 -1.1352 9.9437
GDM-1 GDSC1; CTRP2 3.1988 9.3795 1.6614 24.5234
Pfeiffer CTRP2 3.223 5.8166 3.0245 19.4853
Jiyoye GDSC1 3.2274 5.2728 0.3132 1.0173
ATN-1 GDSC1 3.233 8.9312 -1.2948 10.8083
MOLT-4 GDSC1 3.2749 4.6987 0.5413 0.2384
WSU-NHL GDSC1 3.2804 5.6696 0.1815 1.5732
KMOE-2 GDSC1 3.3072 5.2398 0.359 0.7703
ML-2 GDSC1 3.3083 4.7974 0.5191 0.2764
JSC-1 GDSC1 3.3356 5.1536 0.4023 0.5972
Karpas-620 GDSC1 3.3535 4.5792 0.6092 0.1018
KG-1 GDSC1 3.3542 5.0582 0.444 0.4549
CCRF-CEM GDSC1 3.3581 5.4609 0.2968 0.9767
CRO-AP2 GDSC1 3.376 4.9304 0.4975 0.3023
QIMR-WIL GDSC1 3.381 5.6128 0.2483 1.1628
LP-1 GDSC1; CTRP2 3.3826 5.9489 3.165 18.4916
WIL2 NS GDSC1 3.3934 4.7219 0.5752 0.1429
P30/OHK GDSC1 3.4451 5.1918 0.4308 0.4484
MOTN-1 CTRP2 3.4595 7.7919 2.6092 20.3324
HAL-01 GDSC1 3.5403 10.8207 -1.9887 14.1173
L-1236 GDSC1 3.5979 6.0043 0.191 1.22
H9 GDSC1 3.6009 5.3502 0.4331 0.3724
NALM-6 GDSC1; CTRP2 3.6165 5.2113 3.5671 16.3423
NU-DUL-1 GDSC1; CTRP2 3.6169 7.7476 1.8519 11.8798
Daudi GDSC1; CTRP2 3.6511 5.8494 3.4831 16.5274
BALL-1 GDSC1 3.7041 5.1975 0.5226 0.1575
ROS-50 GDSC1 3.7706 5.9206 0.2933 0.7002
Mono-Mac-6 GDSC1 3.791 7.7714 -0.44 4.3373
RPMI-8402 GDSC1; CTRP2 3.7958 5.3799 3.7347 15.1882
DG-75 GDSC1 3.834 5.6675 0.4077 0.3437
NK-92MI GDSC1 3.8442 5.2102 0.5659 0.0797
ARH-77 GDSC1 3.9106 5.3741 0.5341 0.1047
697 GDSC1; CTRP2 3.9268 6.4076 3.6249 15.1805
SU-DHL-8 GDSC1; CTRP2 3.9522 5.9655 3.7822 14.531
VL51 GDSC1 3.9527 6.0092 0.3315 0.4886
HC-1 GDSC1 3.9553 5.9012 0.3705 0.3865
P3HR-1 CTRP2 3.9984 7.1299 3.4435 15.6566
GR-ST GDSC1 4.0918 16.9827 -4.5842 23.7138
KE-37 GDSC1; CTRP2 4.2413 5.6679 4.1651 12.2737
PL-21 GDSC1 4.3187 6.5939 0.2615 0.5144
KMS-21-BM CTRP2 4.336 6.4106 4.0686 12.3352
SU-DHL-4 GDSC1; CTRP2 4.3448 5.4525 4.3113 11.4361
SU-DHL-6 GDSC1; CTRP2 4.3655 5.5233 4.3236 11.3273
JVM-3 GDSC1; CTRP2 4.3755 8.2516 2.8541 11.3335
SUP-T11 CTRP2 4.3974 5.2964 4.3831 11.0205
Ri-1 CTRP2 4.4168 6.0946 4.2543 11.4134
TALL-1 [Human adult T-ALL] CTRP2 4.4224 5.5533 4.3802 10.9493
KM-H2 GDSC1; CTRP2 4.4318 6.1848 4.2443 11.4044
KHM-1B CTRP2 4.4493 5.6295 4.1769 5.3418
Karpas-299 GDSC1; CTRP2 4.4629 5.0159 4.4619 10.5396
SU-DHL-10 CTRP2 4.4721 6.0509 4.3268 10.9834
AMO1 GDSC1; CTRP2 4.4722 5.7475 4.3996 10.7235
SU-DHL-1 GDSC1; CTRP2 4.4726 7.3158 3.8696 12.7116
Reh GDSC1; CTRP2 4.4815 5.1825 4.4767 10.4283
PF-382 GDSC1; CTRP2 4.4902 6.6059 4.1674 11.5192
DEL GDSC1; CTRP2 4.4989 4.9096 4.4988 10.2964
L-363 GDSC1; CTRP2 4.5209 6.0878 4.3697 10.6799
KMS-11 CTRP2 4.5232 6.0364 4.3864 10.6126
KMS-12-BM GDSC1; CTRP2 4.532 5.5701 4.495 10.2015
SR GDSC1; CTRP2 4.5542 5.5217 4.5253 10.0258
Ki-JK CTRP2 4.5838 5.3197 4.4468 3.8261
KMS-26 CTRP2 4.5868 5.1465 4.5851 9.7165
MOLT-16 GDSC1; CTRP2 4.5869 6.1477 4.4244 10.2824
DB GDSC1; CTRP2 4.6016 6.6295 4.2787 10.7815
Jurkat CTRP2 4.6083 5.7698 4.5427 9.7926
MOLM-16 CTRP2 4.6184 6.2098 4.4401 10.1306
SUP-T1 GDSC1; CTRP2 4.6261 5.8554 4.5438 9.7332
MOLT-3 CTRP2 4.6286 6.618 4.3119 10.5788
KMS-34 CTRP2 4.6299 6.5315 4.3448 10.4508
L-540 GDSC1; CTRP2 4.6441 5.9959 4.5292 9.7293
CA46 GDSC1; CTRP2 4.6733 10.3763 2.6514 17.0591
WSU-DLCL2 GDSC1; CTRP2 4.7272 5.5936 4.7002 8.8669
OCI-AML-2 GDSC1; CTRP2 4.7305 5.406 4.722 8.7819
Raji GDSC1; CTRP2 4.7549 5.598 4.7292 8.6778
MOLM-13 GDSC1; CTRP2 4.7915 11.1845 2.3678 17.8845
OPM-2 GDSC1; CTRP2 4.7962 7.0529 4.3178 10.0932
P12-Ichikawa CTRP2 4.8185 6.4237 4.5867 9.0002
F-36P CTRP2 4.8618 6.9599 4.4252 9.4978
KMS-20 CTRP2 4.8631 7.4204 4.2286 10.2679
DND-41 GDSC1; CTRP2 4.9538 10.8995 2.6573 16.3871
RPMI-6666 GDSC1; CTRP2 4.9627 9.7526 3.2264 14.0879
Namalwa GDSC1; CTRP2 4.9687 9.9749 3.1237 14.4904
NB4 GDSC1; CTRP2 4.9963 5.7354 4.9677 7.0797
HEL GDSC1; CTRP2 5.0642 6.7838 4.7104 7.8411
RS4;11 GDSC1; CTRP2 5.0853 9.6698 3.3812 13.1777
M-07e CTRP2 5.1059 7.8141 4.2929 9.3991
RCH-ACV CTRP2 5.1231 6.9859 4.686 7.7793
Hs 611.T CTRP2 5.1525 7.9677 4.2663 9.3945
U-937 CTRP2 5.1572 5.9244 5.1061 6.087
HPB-ALL CTRP2 5.1643 7.0098 4.7179 7.5454
KE-97 CTRP2 5.1768 6.1473 5.0676 6.166
A4/Fukuda GDSC1; CTRP2 5.1797 6.3187 5.0138 6.3575
RL GDSC1; CTRP2 5.1833 8.9277 3.8344 11.0939
PL21 CTRP2 5.1866 5.955 5.131 5.9073
NOMO-1 GDSC1; CTRP2 5.1939 6.1047 5.0991 6
Mono-Mac-1 CTRP2 5.196 6.9957 4.7566 7.3096
RPMI-8226 GDSC1; CTRP2 5.2026 6.2011 5.0786 6.0495
SKM-1 GDSC1; CTRP2 5.232 6.0037 5.1685 5.6333
KMS-18 CTRP2 5.2355 6.6144 4.96 6.4068
JJN-3 GDSC1; CTRP2 5.2412 6.8357 4.8729 6.7319
ST486 GDSC1; CTRP2 5.2468 15.0267 0.8724 22.137
HuNS1 CTRP2 5.2594 13.7754 1.5067 19.9956
KMS-27 CTRP2 5.2665 6.1312 5.1702 5.5228
NU-DHL-1 CTRP2 5.2786 6.3771 5.099 5.7534
MHH-CALL-4 CTRP2 5.3254 6.2398 5.1988 5.2436
U-698-M GDSC1 5.3292 15.8917 -3.2213 16.0361
L-428 GDSC1; CTRP2 5.3372 6.3655 5.1662 5.3329
BL-70 CTRP2 5.3444 6.0233 5.2861 4.8667
Karpas-422 GDSC1; CTRP2 5.3679 8.4152 4.2569 8.9295
A3/Kawakami GDSC1; CTRP2 5.3722 5.9547 5.3332 4.6129
U266B1 GDSC1; CTRP2 5.4064 6.6263 5.1338 5.2688
SUP-M2 GDSC1; CTRP2 5.411 5.9274 5.3812 4.3224
KO52 CTRP2 5.4326 5.9264 5.4048 4.1713
EJM GDSC1; CTRP2 5.4808 6.3318 5.3324 4.296
TF-1 CTRP2 5.4984 6.2206 5.3926 4.0181
OCI-AML-3 GDSC1; CTRP2 5.5004 6.0152 5.4585 3.77
OCI-Ly10 CTRP2 5.5068 6.7824 5.168 4.8723
Kasumi-2 CTRP2 5.5304 6.4666 5.3305 4.1674
Ci-1 CTRP2 5.5678 6.097 5.509 3.3831
SIG-M5 GDSC1; CTRP2 5.573 6.0909 5.5166 3.3395
MHH-CALL-3 CTRP2 5.5898 6.6438 5.3145 4.0752
MOLT-13 GDSC1; CTRP2 5.6229 6.2353 5.5211 3.1781
CMK CTRP2 5.6586 13.5453 1.9678 17.4915
Granta-519 GDSC1; CTRP2 5.6736 6.3551 5.5268 3.0168
OCI-M1 GDSC1; CTRP2 5.6756 6.221 5.583 2.7941
MOLP-2 CTRP2 5.686 7.0408 5.2232 4.2119
SK-MM-2 GDSC1; CTRP2 5.6893 6.5052 5.4776 3.1699
OCI-Ly3 CTRP2 5.6992 6.499 5.4904 3.0936
HL-60 GDSC1; CTRP2 5.7248 6.3407 5.5862 2.6473
OCI-AML-5 GDSC1; CTRP2 5.8037 6.3766 5.6512 2.1845
HDLM-2 GDSC1; CTRP2 5.8111 10.246 3.7461 10.1116
OCI-Ly19 GDSC1; CTRP2 5.8404 6.6282 5.5689 2.4309
EHEB GDSC1; CTRP2 5.9134 9.9248 3.2851 6.2928
THP-1 GDSC1; CTRP2 5.9426 6.981 5.4888 2.5397
NCI-H929 CTRP2 6.0028 12.1171 2.9733 12.9042
HuT 78 CTRP2 6.5633 21.6373 -1.324 25.4637
SET-2 CTRP2 6.6203 14.2661 2.403 13.9685
ME1 CTRP2 6.698 8.4808 5.3184 1.9967
SEM CTRP2 6.8715 8.1189 5.5883 0.792
AML-193 CTRP2 7.1595 11.759 4.0547 6.4348
JeKo-1 CTRP2 7.396 15.774 2.2549 13.1571
MV4-11 GDSC1; CTRP2 7.4375 10.3579 4.9084 2.6612
SUP-HD1 GDSC1; CTRP2 7.5944 15.4915 2.5421 11.7487
P31/FUJ GDSC1; CTRP2 7.6151 9.5528 5.3618 0.9146
MM1.S CTRP2 8.0795 9.9421 5.4193 0.49
HT GDSC1; CTRP2 8.1453 9.5603 5.5858 0.1612
HD-MY-Z CTRP2 8.1996 15.4441 2.9968 9.0792
MOLP-8 GDSC1; CTRP2 8.2096 10.3112 5.3329 0.6303
JVM-2 GDSC1; CTRP2 8.2828 10.4085 5.3271 0.6079
HEL 92.1.7 CTRP2 10.254 25.5297 -0.4521 17.3431
⏷ Show the Full List of 207 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 5.4879 6.6022 5.2286 4.6803
TE15 CTRP2 5.868 7.0181 5.4037 3.0539
TE-15 GDSC1 2.4521 4.3891 0.3079 1.9409
TE-8 GDSC1 3.9028 5.84 0.3726 0.4021
OE21 CTRP2 4.9918 6.9793 4.5528 8.6506
TE-6 GDSC1; CTRP2 5.0436 6.3035 4.8719 7.2822
KYSE-70 CTRP2 5.352 8.0141 4.4363 8.2263
KYSE-410 CTRP2 5.3556 6.8339 4.9913 5.9647
TE-4 CTRP2 5.4006 6.5216 5.1717 5.1363
TE-11 GDSC1; CTRP2 5.4208 9.9364 3.557 11.7124
KYSE-30 CTRP2 5.421 6.9358 5.0121 5.7143
TE-5 GDSC1; CTRP2 5.4541 6.6362 5.179 4.9648
TE-14 CTRP2 5.4826 18.4745 -0.6448 25.9398
OE19 CTRP2 5.6651 17.3583 0.0684 23.6624
KYSE-520 CTRP2 5.6723 6.9657 5.2461 4.1502
KYSE-140 CTRP2 5.7554 11.5768 3.0338 13.1557
KYSE-510 CTRP2 5.7811 6.7193 5.4685 2.9818
OE33 CTRP2 5.7824 6.75 5.455 3.0344
KYSE-450 CTRP2 5.9401 6.5455 5.7024 1.6522
EC-GI-10 GDSC1; CTRP2 6.8421 12.078 3.6639 8.5473
KYSE-150 CTRP2 7.1067 9.0952 5.287 1.6243
COLO 680N CTRP2 7.839 9.3582 5.5398 0.3315
TE-1 GDSC1; CTRP2 7.9397 10.7567 5.0173 1.7545
TE-9 GDSC1; CTRP2 8.1373 10.3171 5.2984 0.7565
KYSE-180 CTRP2 8.1507 14.1286 3.5941 6.8394
TE-10 GDSC1; CTRP2 8.2025 10.7995 5.1336 1.1759
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 8.0255 15.0988 3.043 9.157
MZ-PC-1 GDSC1 3.9436 6.2815 0.2296 0.8106
SU.86.86 CTRP2 4.5604 5.8636 4.4704 10.1978
MIA PaCa-2 CTRP2 4.6005 6.4899 4.3278 10.5997
HuP-T4 CTRP2 4.8056 8.0579 3.8822 11.8004
HPAC CTRP2 4.8802 6.4394 4.6477 8.5939
QGP-1 CTRP2 5.0931 6.836 4.1889 3.7532
SW1990 CTRP2 5.1533 11.026 2.7769 15.4671
CFPAC-1 CTRP2 5.2382 7.028 4.7854 7.0864
PANC-1 CTRP2 5.2954 8.1827 4.3011 8.9141
SNU-213 CTRP2 5.306 6.8253 4.3615 2.5749
YAPC CTRP2 5.3112 7.9115 4.4466 8.2794
PaTu 8988s CTRP2 5.3407 6.0491 5.2751 4.9178
Capan-2 CTRP2 5.3439 7.473 4.6866 7.2208
Panc 08.13 CTRP2 5.347 7.0529 4.8844 6.4131
BxPC-3 CTRP2 5.4304 10.3871 3.3423 12.5758
Panc 04.03 CTRP2 5.4535 7.7056 4.6815 6.9815
Capan-1 CTRP2 5.5106 11.4351 2.8922 14.234
TCC-Pan2 CTRP2 5.5441 10.2931 3.49 11.7259
Hs 766T CTRP2 5.5764 6.2336 5.4719 3.496
KP-2 CTRP2 5.606 6.1909 5.5192 3.2333
KP-3 CTRP2 5.6428 7.0397 5.1823 4.4813
HPAF-II CTRP2 5.9004 7.9005 4.2511 2.1417
PK-45H CTRP2 5.9084 7.2283 5.3357 3.2524
Panc 10.05 CTRP2 5.9198 10.1494 3.8871 9.3055
KP-4 CTRP2 5.9708 6.7141 5.6464 1.8208
HuP-T3 CTRP2 6.015 8.0304 5.0268 4.3345
PSN1 GDSC1; CTRP2 6.7897 16.2346 1.5563 16.7512
DAN-G CTRP2 7.0107 27.9575 -4.1177 29.9903
PaTu 8988t CTRP2 7.4228 18.3442 1.0021 17.4761
L3.3 CTRP2 7.7399 10.3361 5.0925 1.6815
Panc 03.27 CTRP2 7.7515 13.5704 3.5916 7.4117
Panc 05.04 CTRP2 7.8745 9.643 5.4461 0.5254
SUIT-2 CTRP2 8.0901 9.9492 5.421 0.4812
PK-59 CTRP2 8.2411 14.8325 3.3187 7.7819
Panc 02.03 CTRP2 8.3997 11.8195 4.803 2.0633
AsPC-1 CTRP2 9.1789 21.9341 0.5361 16.0969
PaTu 8902 CTRP2 13.4453 34.1259 -2.4109 17.9926
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 62 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 4.4028 6.4758 4.1189 13.8097
LB2518-MEL GDSC1 1.2936 2.9853 0.2402 5.0092
LB373-MEL-D GDSC1 2.0228 3.5098 0.4601 1.6863
MZ-MEL-7 GDSC1 2.3461 3.9375 0.4436 1.3118
IST-MEL1 GDSC1 2.6325 4.9592 0.1584 2.5655
SH-4 GDSC1 2.667 4.4501 0.3871 1.2234
GAK GDSC1 2.7138 3.9229 0.6065 0.2989
CP66-MEL GDSC1 2.8296 4.2644 0.5278 0.4811
MMAc-SF GDSC1 2.8654 4.4253 0.4827 0.6191
A-388 GDSC1 3.0257 5.7121 0.0412 2.6636
DJM-1 GDSC1 3.5211 5.542 0.3333 0.7185
MZ-MEL-2 GDSC1 3.8584 5.8011 0.3699 0.4274
CP67-MEL GDSC1 3.9084 7.4255 -0.2346 2.991
Mel Ho CTRP2 4.2636 5.2926 4.2431 11.9331
G-361 CTRP2 4.3338 8.3875 3.2583 15.4845
Hs 940.T CTRP2 4.3962 6.6252 4.0593 12.1956
RPMI-7951 CTRP2 4.6501 5.6623 4.6074 9.4345
MeWo CTRP2 4.892 7.0127 4.4348 9.3791
Mel JuSo CTRP2 5.2268 5.9659 5.1723 5.6358
WM115 CTRP2 5.309 5.8545 5.2846 4.9825
SK-MEL-3 CTRP2 5.3803 5.9246 5.3485 4.5338
UACC-257 GDSC1; CTRP2 5.382 6.1465 5.2912 4.735
IGR-1 CTRP2 5.4216 6.1822 5.3226 4.5024
LOX-IMVI GDSC1; CTRP2 5.457 11.212 2.9561 14.0907
IGR-37 CTRP2 5.4767 5.9132 5.4551 3.8559
K029AX CTRP2 5.4864 5.9992 5.4472 3.8533
WM88 CTRP2 5.549 6.0386 5.5053 3.4532
Hs 944.T CTRP2 5.5618 6.1008 5.5013 3.4292
RVH-421 CTRP2 5.5873 10.0859 3.6311 11.0511
HT-144 GDSC1; CTRP2 5.5908 6.0767 5.5402 3.2
WM266-4 CTRP2 5.6407 6.1275 5.5787 2.9104
COLO 800 GDSC1; CTRP2 5.6414 6.295 5.5177 3.1394
CJM [Human melanoma] CTRP2 5.6637 6.5673 5.4237 3.4506
UACC-62 CTRP2 5.7718 6.3189 5.6442 2.2949
WM983B CTRP2 5.783 9.4243 4.132 8.5563
Hs 934.T CTRP2 5.7846 6.3955 5.6234 2.3445
SK-MEL-1 GDSC1; CTRP2 5.8387 6.4936 5.6316 2.1777
SK-MEL-24 CTRP2 5.873 10.1381 3.853 9.541
WT2-iPS CTRP2 6.0872 7.0625 5.5705 1.9108
A101D GDSC1; CTRP2 6.3203 17.0236 0.783 20.2109
SK-MEL-2 GDSC1; CTRP2 6.6994 10.2821 4.4436 5.5646
SK-MEL-28 CTRP2 7.0955 8.0181 5.7365 0.22
SK-MEL-30 CTRP2 7.317 8.5448 5.6291 0.3635
A2058 CTRP2 7.4326 20.0786 0.148 20.0739
Hs 688(A).T CTRP2 7.4335 15.2492 2.5422 12.013
Hs 852.T CTRP2 7.5115 9.25 5.4363 0.7667
Hs 936.T CTRP2 7.7337 9.317 5.5112 0.4397
SK-MEL-5 CTRP2 7.8054 9.1456 5.6048 0.2204
WM1799 CTRP2 7.8539 9.6082 5.4506 0.5248
Hs 294T CTRP2 7.8544 11.2789 4.7374 2.8278
MDA-MB-435S CTRP2 7.8808 9.789 5.3915 0.6592
IPC-298 CTRP2 7.9491 9.1967 5.641 0.1299
SK-MEL-31 CTRP2 8.0622 9.2631 5.6588 0.0897
COLO 792 CTRP2 8.3127 19.9037 0.9023 16.3065
WM793 CTRP2 8.3591 10.5412 5.3089 0.6139
A-375 CTRP2 8.5526 10.2767 5.4846 0.2095
Malme-3M CTRP2 8.8725 11.1039 5.3096 0.4053
Hs 839.T CTRP2 10.1871 28.719 -2.0532 21.3062
Hs 895.T CTRP2 10.2775 22.3911 1.0726 12.8979
COLO 829 GDSC1; CTRP2 11.4617 27.3621 -0.5079 15.8895
IGR-39 CTRP2 13.2466 48.8365 -9.6864 29.0479
HMCB CTRP2 13.405 27.846 0.4954 10.933
⏷ Show the Full List of 62 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCE-4 GDSC1 3.2629 5.381 0.2868 1.1001
TE-12 GDSC1 4.8005 7.526 0.1116 0.7066
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; CTRP2 5.683 7.7921 4.8536 5.7494
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-5 GDSC1 1.6372 4.9832 -0.4888 9.5604
SJNB-10 GDSC1 2.3537 8.7779 -1.8265 16.3811
SK-N-DZ GDSC1 2.3696 3.6367 0.574 0.6412
GOTO GDSC1 2.6354 5.9052 -0.2609 5.3215
SJNB-14 GDSC1 2.6755 4.6765 0.2992 1.6779
SK-N-BE(2)-M17 GDSC1 2.6982 4.5132 0.3762 1.2435
KP-N-YS GDSC1 2.7083 5.8655 -0.1997 4.7543
SJNB-6 GDSC1 2.7171 11.8977 -3.0924 21.6953
CHP-126 GDSC1 2.8338 5.879 -0.1339 4.0756
SiMa GDSC1 2.9472 5.4747 0.1014 2.4263
LA-N-6 GDSC1 3.1214 4.7956 0.4487 0.5709
NB(TU)1 GDSC1 3.1285 5.1431 0.3205 1.0727
SJNB-17 GDSC1 3.1529 5.8343 0.0538 2.4086
GI-ME-N GDSC1 3.3902 6.0101 0.0958 1.8812
SJNB-5 GDSC1 3.4685 5.9318 0.1626 1.4689
KP-N-YN GDSC1 3.5596 5.5339 0.3515 0.6324
TGW GDSC1 3.5746 5.2871 0.4456 0.3517
KP-N-RT-BM-1 GDSC1 3.6393 12.7644 -2.8543 18.2064
SJNB-13 GDSC1 3.6916 5.298 0.4841 0.2273
NH-12 GDSC1 3.7903 5.7551 0.3606 0.4828
NB69 GDSC1 3.9372 5.8878 0.3686 0.3984
Kelly GDSC1; CTRP2 4.531 5.2426 4.525 10.1025
IMR-32 CTRP2 4.7493 7.1443 4.2305 10.5597
SJNB-7 GDSC1 4.8246 19.4072 -5.2439 24.0888
NB1 GDSC1; CTRP2 5.0279 5.9119 4.9682 6.9783
SK-N-FI GDSC1; CTRP2 5.383 6.0624 5.3176 4.6356
SK-N-AS CTRP2 5.4735 6.0137 5.4295 3.9567
KP-N-SI9s CTRP2 5.5392 6.1292 5.4677 3.6196
CHP-212 CTRP2 5.7166 6.4792 5.5169 2.9437
MHH-NB-11 GDSC1; CTRP2 7.5593 9.8883 5.1898 1.5161
SK-N-SH CTRP2 8.7808 22.2069 0.1147 17.9429
SK-N-BE(2) CTRP2 8.8843 10.5522 5.5093 0.1186
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 CTRP2 4.6208 5.8179 4.5462 9.7413
SNU-869 CTRP2 5.4445 11.6437 2.7303 15.0197
SNU-308 CTRP2 6.9776 9.8898 4.8328 3.5482
SNU-1196 CTRP2 7.6589 10.4154 5.0126 2.0377
SNU-478 CTRP2 7.7213 9.5785 5.4023 0.7256
SNU-245 CTRP2 7.7747 10.2073 5.1667 1.4031
HuH-28 CTRP2 7.82 9.3382 5.5395 0.3396
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NOS-1 [Human HNSCC] GDSC1 0.7908 6.302 -1.8273 21.6941
ES1 GDSC1 1.8464 4.0999 0.0859 4.6556
EW-13 GDSC1 2.2926 4.813 0.0327 4.0203
EW-1 GDSC1 2.3615 4.8934 0.0368 3.8503
SK-PN-DW GDSC1 2.3722 5.636 -0.2986 6.1739
ES7 GDSC1 2.5872 5.3544 -0.04 3.9226
EW-24 GDSC1 2.7521 3.9172 0.6228 0.2391
ES4 GDSC1 2.962 6.381 -0.2848 4.821
TC-71 GDSC1 3.1333 5.436 0.2073 1.6073
EW-22 GDSC1 3.1858 11.6456 -2.6295 18.312
EW-18 GDSC1 3.2976 12.4433 -2.9383 19.4528
EW-12 GDSC1 3.3061 5.1808 0.3805 0.6916
H-EMC-SS GDSC1 3.3507 6.226 -0.0114 2.505
ES5 GDSC1 3.4372 6.4594 -0.0656 2.6907
EW-3 GDSC1 3.8685 6.8746 -0.0299 1.9759
EW-16 GDSC1 3.9597 6.0732 0.3113 0.5418
ES8 GDSC1 4.0371 5.7859 0.4396 0.2167
EW-11 GDSC1 4.0937 12.4463 -2.3958 14.931
ES6 GDSC1 4.1936 6.4633 0.2608 0.5733
MHH-ES-1 CTRP2 4.716 5.8647 4.6394 9.1144
A-673 CTRP2 4.8135 5.925 4.7317 8.4841
SW1353 CTRP2 5.1106 5.9625 4.6393 1.6919
SK-N-MC CTRP2 5.3312 5.8271 5.3128 4.8138
MG-63 CTRP2 5.3489 5.9248 5.3144 4.7523
TC71 CTRP2 5.4068 6.0024 5.3596 4.4117
CAL-78 CTRP2 5.4278 6.8538 5.056 5.5214
SJSA-1 GDSC1; CTRP2 5.6606 6.4101 5.49 3.1956
G-292 clone A141B1 CTRP2 5.7203 15.38 1.1038 20.3816
Hs 888.T CTRP2 6.0031 21.5039 -1.7198 27.397
SK-ES-1 GDSC1; CTRP2 6.7 9.14 5.0031 3.2618
Hs 822.T CTRP2 7.0444 8.0193 5.7141 0.2952
U2OS CTRP2 7.6496 9.3211 4.5048 0.174
SaOS-2 CTRP2 8.259 9.8727 5.5175 0.2342
HOS CTRP2 14.4079 30.7513 -0.2309 11.8446
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 80 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC1 2.6602 4.0796 0.528 0.5954
MRK-nu-1 GDSC1 2.7027 5.7151 -0.1352 4.3338
COLO 824 GDSC1 2.9742 6.9299 -0.5259 6.397
HCC1187 GDSC1 3.0593 5.9082 -0.0248 3.0059
MFM-223 GDSC1 3.307 4.716 0.5468 0.2166
Evsa-T GDSC1 3.3674 4.778 0.547 0.1984
HCC2157 GDSC1 3.3983 4.9579 0.496 0.2974
OCUB-M GDSC1 3.4728 5.0991 0.4739 0.322
HCC1599 GDSC1 4.0861 11.5728 -1.9891 12.8456
Hs 578T CTRP2 4.2142 9.2437 2.7461 17.8062
UACC-812 GDSC1 4.4055 16.8623 -4.3035 22.0901
MDA-MB-157 CTRP2 4.7856 12.8264 0.9357 18.4424
HCC1954 CTRP2 4.8728 6.6577 4.0906 4.6638
EFM-192A CTRP2 4.9539 10.9559 2.6297 16.4956
ZR-75-30 CTRP2 4.9567 9.1805 3.4979 12.9971
SK-BR-3 CTRP2 4.9623 15.4255 0.4241 24.1406
HMC-1-8 CTRP2 4.9758 5.9961 4.891 7.4144
HCC38 CTRP2 5.0836 7.4676 4.4309 8.8974
MDA-MB-453 CTRP2 5.1191 9.6538 3.4206 12.9401
T-47D CTRP2 5.147 9.0206 3.7553 11.5024
MDA-MB-468 CTRP2 5.2534 10.8859 2.9365 14.6087
MDA-MB-231 CTRP2 5.3268 6.6599 5.0368 5.8611
BT-474 GDSC1; CTRP2 5.41 6.1268 5.328 4.5168
HCC1428 CTRP2 5.4334 10.9053 3.0877 13.6089
HCC202 CTRP2 5.4527 10.1853 3.4623 12.0347
KPL-1 CTRP2 5.5011 5.9598 5.4723 3.7189
HCC1806 CTRP2 5.5112 7.2518 4.3014 2.4953
CAL-85-1 CTRP2 5.5555 9.4635 3.9121 9.95
MCF-7 CTRP2 5.5803 7.9157 4.0271 3.5849
BT-549 CTRP2 5.6083 6.2643 5.4945 3.3202
HCC2218 GDSC1; CTRP2 5.6756 6.6602 5.3932 3.5437
HCC1419 CTRP2 5.7527 8.5819 4.525 6.9726
AU565 CTRP2 5.8085 9.5754 4.0787 8.7274
MDA-MB-361 CTRP2 5.902 7.1874 5.3502 3.2048
CAMA-1 CTRP2 5.9514 9.8608 3.3439 5.971
CAL-120 CTRP2 6.0303 6.9927 5.5584 2.07
CAL-51 CTRP2 6.2472 7.9572 5.2513 2.9624
Hs 578Bst CTRP2 6.602 8.9112 5.0449 3.2393
BT-20 CTRP2 6.9732 13.3871 3.1155 10.5486
HCC1937 CTRP2 7.5655 11.6042 4.407 4.4391
HCC1500 GDSC1; CTRP2 7.6613 26.8415 -3.0393 27.1034
CAL-148 GDSC1; CTRP2 7.8476 9.0642 5.65 0.1394
JIMT-1 CTRP2 7.9974 9.5319 5.5393 0.2756
HCC1143 CTRP2 8.0859 11.8961 4.5939 3.1023
HDQ-P1 CTRP2 8.1929 9.542 5.6096 0.1218
HCC1395 CTRP2 8.2017 10.6577 5.1913 1.0092
BT 416 CTRP2 4.4888 7.5929 3.7686 13.0642
BT 231 CTRP2 5.1969 7.734 4.4199 8.6619
BT 145 CTRP2 5.3822 7.6189 4.6547 7.2592
BT 228 CTRP2 5.4146 5.8909 5.3921 4.2729
BT 139 CTRP2 5.4436 5.9562 5.4105 4.1167
BT 112 CTRP2 5.4712 5.9855 5.4339 3.9476
BT 187 CTRP2 5.5071 6.2379 5.3958 3.9813
BT 239 CTRP2 5.586 5.9213 5.5716 3.1032
BT164 CTRP2 5.5868 6.161 5.5089 3.3273
BT 159 CTRP2 5.6613 6.0501 5.6247 2.6804
BT 224 CTRP2 5.9707 12.365 2.8225 13.5716
BT 216 CTRP2 6.0292 9.5951 4.2563 7.5442
BT 179 CTRP2 6.2125 8.9228 4.7428 5.1551
BT 422 CTRP2 6.3582 8.5301 5.0524 3.6021
BT 271 CTRP2 6.3648 9.1019 4.7738 4.7535
BT 286 CTRP2 6.3836 8.5541 5.0598 3.5284
BT 172 CTRP2 6.4248 10.8026 3.9744 7.9879
BT 328 CTRP2 6.4603 8.5345 5.1266 3.1254
BT 444 CTRP2 6.4656 7.9037 5.438 1.8415
BT147 CTRP2 6.4693 8.3658 5.216 2.7428
BT 131 CTRP2 6.4744 9.5934 4.6143 5.2304
BT 359 CTRP2 6.5533 12.6053 3.1778 11.0368
BT 440 CTRP2 6.5971 11.6397 3.6929 8.8502
BT 498 CTRP2 6.6093 8.2026 5.392 1.8245
BT 428 CTRP2 6.6149 8.7753 5.1202 2.9122
BT 232 CTRP2 6.6359 11.1293 3.9765 7.6088
BT 320 CTRP2 6.6561 8.9588 5.0602 3.095
BT 330 CTRP2 6.6784 9.1827 4.9671 3.4414
BT 333 CTRP2 6.6936 8.728 5.1975 2.4845
BT 245 CTRP2 6.7321 10.5996 4.3114 6.0583
BT 340 CTRP2 6.8945 10.0103 4.7175 4.1345
BT 504 CTRP2 7.0227 10.9251 4.3635 5.3844
BT 482 CTRP2 7.2306 8.7366 5.5112 0.7447
BT 248 CTRP2 7.6195 9.5722 5.3559 0.9293
⏷ Show the Full List of 80 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.9362 9.2272 5.6255 0.1534
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D-336MG GDSC1 2.0797 4.4446 0.0727 4.2003
D-263MG GDSC1 3.0499 4.4906 0.5313 0.352
Onda 10 GDSC1 3.0564 4.8778 0.3915 0.8326
D-247MG GDSC1 3.343 10.407 -1.9233 14.2443
D-502MG GDSC1 3.4282 5.6863 0.2404 1.1555
GI-1 GDSC1 3.6253 5.3435 0.4444 0.3347
KNS-81-FD GDSC1 3.6755 5.5104 0.4043 0.4156
Onda 11 GDSC1 3.6907 6.3462 0.0988 1.5462
KINGS-1 GDSC1 4.3732 20.2923 -5.9997 27.0032
KS-1 [Human Krukenberg tumour] GDSC1 4.4793 6.5847 0.3232 0.3131
AM-38 GDSC1; CTRP2 4.6662 6.0556 4.5373 9.633
SF268 GDSC1; CTRP2 4.6972 6.6586 4.3703 10.1633
LN-18 CTRP2 4.7977 5.7579 4.75 8.4688
KNS-60 CTRP2 4.8681 5.4227 4.8634 7.8523
CAS-1 GDSC1; CTRP2 4.8944 6.4247 4.6682 8.4758
Hs 683 CTRP2 5.0342 10.9535 2.7043 16.0202
SNU-1105 CTRP2 5.2009 6.1141 4.6337 1.5498
SF539 GDSC1; CTRP2 5.2142 9.5337 3.5673 12.1239
KNS-81 CTRP2 5.3368 5.946 5.2966 4.8527
KG-1-C CTRP2 5.4089 5.9248 5.3795 4.3349
SW1088 CTRP2 5.4138 6.354 5.2524 4.7889
DK-MG CTRP2 5.4783 14.2392 1.4662 19.6649
Daoy CTRP2 5.5353 7.2027 5.0009 5.479
D283 Med GDSC1; CTRP2 5.5828 6.088 5.5281 3.2682
CCF-STTG1 CTRP2 5.618 13.7616 1.8249 18.0984
GaMG CTRP2 5.6687 6.4376 5.4864 3.1886
A-172 CTRP2 5.6719 6.2505 5.5676 2.8633
DBTRG-05MG CTRP2 5.729 6.784 5.3874 3.4375
SNB-75 GDSC1; CTRP2 5.7418 7.7102 4.9476 5.2297
GB-1 GDSC1; CTRP2 5.7484 6.5852 5.5001 2.9314
KNS-42 GDSC1; CTRP2 5.7763 13.5813 2.0503 16.9431
KALS-1 GDSC1; CTRP2 5.8487 6.919 5.4349 2.9662
U-251MG CTRP2 5.8618 6.4927 5.6545 2.0292
YKG-1 CTRP2 5.9064 6.4915 5.6975 1.7483
NMC-G1 GDSC1; CTRP2 5.9103 6.8718 5.5143 2.5014
SF126 GDSC1; CTRP2 5.9369 7.6673 5.1417 4.0074
42-MG-BA CTRP2 6.0551 16.213 0.9691 20.1401
U-118MG CTRP2 6.3714 14.6106 2.0307 15.8359
Becker GDSC1; CTRP2 6.478 10.3354 4.2486 6.7501
U-87MG ATCC GDSC1; CTRP2 6.7211 8.8327 4.2978 1.1045
T98G CTRP2 6.9916 13.5318 3.0578 10.7473
SF295 CTRP2 7.0451 8.6603 5.4462 1.1177
SNU-489 CTRP2 7.3276 8.7547 5.5507 0.5619
SNU-466 CTRP2 7.5109 8.7102 5.6478 0.2396
SNU-201 CTRP2 7.5672 9.5613 5.3343 1.0352
ONS-76 GDSC1; CTRP2 7.8101 11.8672 4.44 3.9993
SNU-626 CTRP2 7.9733 9.2631 5.6266 0.1436
SNU-738 CTRP2 8.0785 9.3552 5.6329 0.1151
8-MG-BA GDSC1; CTRP2 8.2026 14.0125 3.6835 6.4227
LN-229 CTRP2 8.6899 10.1541 5.5762 0.083
TM-31 CTRP2 9.9629 24.6661 -0.2375 17.1733
YH-13 CTRP2 10.1523 29.4498 -2.4363 22.1735
GOS-3 CTRP2 11.5561 20.6481 2.6632 6.2648
M059K CTRP2 15.6352 36.9728 -2.3453 15.5405
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC1 1.5627 3.8897 -0.007 6.1168
ETK-1 GDSC1 2.7916 4.687 0.3497 1.2729
TGBC1TKB GDSC1 3.3789 4.9845 0.4795 0.3457
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-6 CTRP2 4.7122 5.607 4.6824 8.9765
RL95-2 GDSC1; CTRP2 5.0669 6.1651 4.5027 2.3932
HEC-1-A CTRP2 5.1171 6.6345 4.8269 7.2455
JHUEM-1 CTRP2 5.2886 6.6413 5.0047 6.089
MFE-296 CTRP2 5.3153 6.7699 4.9778 6.1235
JHUEM-7 CTRP2 5.4368 6.7838 5.0964 5.3373
HEC-50B CTRP2 5.4931 7.4892 4.8234 6.3057
EN CTRP2 5.4975 11.2957 2.9502 14.0285
AN3-CA CTRP2 5.498 10.6216 3.2859 12.6632
KLE GDSC1; CTRP2 5.7346 6.7014 5.432 3.242
HEC-1-B CTRP2 5.7912 7.625 4.3107 2.0414
JHUEM-3 CTRP2 5.9014 7.1723 5.3573 3.1765
HEC-151 CTRP2 6.0357 7.2282 5.4453 2.5351
EFE-184 CTRP2 6.079 7.2087 5.4908 2.2608
HEC-108 CTRP2 6.9138 13.2296 3.1482 10.5194
MFE-319 CTRP2 7.5769 9.9623 5.167 1.5777
HEC-251 CTRP2 7.6339 10.7642 4.8407 2.6902
HEC-265 CTRP2 7.6772 9.5461 5.3946 0.7755
ESS-1 CTRP2 7.9343 13.9864 3.5166 7.4439
HEC-59 CTRP2 7.979 10.5571 5.1234 1.3748
JHUEM-2 CTRP2 8.8078 10.5876 5.4697 0.1751
Ishikawa (Heraklio) 02 ER- CTRP2 7.9097 9.2199 5.6181 0.1703
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB2241-RCC GDSC1 0.692 2.5737 -0.0562 9.5156
A-498 GDSC1 0.8931 2.7251 0.0469 7.9123
TUHR14TKB CTRP2 1.1448 3.778 -2.8188 1.2467
LB1047-RCC GDSC1 2.2225 5.5649 -0.3617 6.9909
BB65-RCC GDSC1 2.8765 5.0763 0.232 1.7861
A-704 GDSC1 3.016 4.8752 0.3753 0.9339
LB996-RCC GDSC1 3.8933 5.6222 0.4447 0.2457
HA7-RCC GDSC1 4.1643 6.3603 0.2864 0.5158
TK-10 GDSC1 4.4657 6.3708 0.3911 0.1973
KMRC-3 CTRP2 4.5012 6.1981 4.3159 10.9353
RXF 393L GDSC1 4.5161 6.8791 0.2343 0.5014
TUHR10TKB CTRP2 4.6764 5.1499 4.6756 19.5828
769-P CTRP2 4.9887 5.9296 4.5545 2.3241
UO-31 CTRP2 5.0772 8.7851 3.8032 11.4672
BFTC-909 CTRP2 5.2881 6.7711 4.9492 6.3077
KMRC-2 CTRP2 5.4043 5.8579 5.3865 4.3252
KMRC-1 CTRP2 5.453 13.5037 1.8111 18.4969
CAL-54 CTRP2 5.4737 6.2609 5.3514 4.2439
VMRC-RCZ CTRP2 5.7778 6.4063 5.6117 2.4084
OS-RC-2 GDSC1; CTRP2 5.882 7.8237 4.2753 2.0664
ACHN CTRP2 6.6871 11.0952 4.0326 7.2888
786-O CTRP2 7.0071 13.1558 3.2557 9.9283
VMRC-RCW CTRP2 7.7818 9.7385 5.366 0.7884
RCC10RGB GDSC1; CTRP2 7.918 9.7517 5.4228 0.5598
SNU-1272 CTRP2 8.0822 9.4134 5.6141 0.1373
KMRC-20 CTRP2 8.1374 9.702 5.5322 0.2446
Caki-1 CTRP2 10.9737 19.3347 2.9186 6.0009
Caki-2 CTRP2 13.4794 25.3839 1.6423 7.5873
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 320HSR GDSC1 2.9867 4.5841 0.4728 0.5727
HT115 CTRP2 4.0304 5.0857 4.0161 13.4656
NCI-H508 CTRP2 4.2185 11.5809 1.6384 21.9418
NCI-H747 GDSC1; CTRP2 4.4337 7.3689 3.8067 13.0619
SNU-81 CTRP2 4.5723 5.9053 4.4736 10.1497
LS513 GDSC1; CTRP2 4.7137 5.752 4.6603 9.0481
T84 CTRP2 4.7588 6.5929 4.461 9.6448
SNU-407 CTRP2 4.7717 8.4167 3.6821 12.6911
SNU-C2B GDSC1 4.844 7.0337 0.2987 0.2604
RKO GDSC1; CTRP2 4.8845 6.5661 4.6057 8.7403
SNU-C1 GDSC1; CTRP2 4.9928 7.2457 4.4384 9.0992
COLO201 CTRP2 5.1444 6.6028 4.8685 7.0099
CW-2 GDSC1; CTRP2 5.1993 6.9213 4.7925 7.1591
CL-11 GDSC1; CTRP2 5.332 6.5437 5.0904 5.6383
SNU-1033 CTRP2 5.3855 7.0049 4.9449 6.0736
LS1034 GDSC1; CTRP2 5.3917 8.0034 4.4791 7.9579
HCT 15 CTRP2 5.4208 6.3295 5.2693 4.7051
NCI-H716 GDSC1; CTRP2 5.4394 10.1848 3.4506 12.1112
CCK-81 CTRP2 5.5318 6.3666 5.373 3.9989
C2BBe1 GDSC1; CTRP2 5.6518 6.5014 5.4411 3.4117
SW948 CTRP2 5.7017 6.4805 5.5011 3.0445
RCM-1 [Human ESC] CTRP2 5.7079 6.3904 5.5473 2.8453
SW1417 CTRP2 5.7292 6.5526 5.4961 2.9953
SNU-C5 CTRP2 5.7553 6.8551 5.3786 3.4116
HCT 8 CTRP2 5.786 6.5424 5.5571 2.6082
COLO 678 CTRP2 5.7882 7.2256 5.2288 3.9571
KM12 GDSC1; CTRP2 5.8625 6.9778 5.4187 3.0036
SNU-C4 CTRP2 5.9009 6.4817 5.6971 1.7628
SNU-503 CTRP2 5.9178 6.9184 5.4978 2.5542
GP2d CTRP2 5.9533 7.0139 5.4818 2.5464
COLO205 CTRP2 5.9847 8.2754 4.1291 2.5346
HCC-56 CTRP2 6.0782 6.9318 5.6286 1.6837
SNU-C2A CTRP2 6.7706 10.3742 3.6438 3.504
HT-55 CTRP2 7.0099 9.3854 5.0937 2.4717
HCT 116 CTRP2 7.6622 9.1107 5.5597 0.3621
LS411N GDSC1; CTRP2 7.6728 9.086 5.5735 0.3278
SK-CO-1 CTRP2 7.7317 9.243 5.5387 0.3782
LS180 CTRP2 7.8227 9.6086 5.4367 0.5756
DLD-1 CTRP2 7.8361 8.9552 5.6838 0.0992
HT-29 CTRP2 7.8452 9.2948 5.5659 0.2778
LS123 GDSC1; CTRP2 7.8696 10.3038 5.1747 1.2995
COLO 320 CTRP2 7.8897 10.4017 5.1435 1.3827
MDST8 GDSC1; CTRP2 8.0532 9.259 5.657 0.0928
OUMS-23 CTRP2 8.1143 9.3222 5.657 0.0839
LoVo CTRP2 8.1455 10.5076 5.2257 0.9487
SW48 CTRP2 8.2227 10.1455 5.4022 0.4647
SNU-61 CTRP2 8.2854 10.6062 5.2508 0.7964
SW620 CTRP2 8.5525 10.2723 5.4862 0.2074
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 3.5486 5.1961 0.4678 0.308
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2 4.0579 6.7767 3.6402 14.7424
JHH-5 CTRP2 4.2216 8.7172 2.9957 16.8083
Hep-G2 CTRP2 4.4062 6.6604 4.0573 12.1746
HuH-6 CTRP2 4.4205 6.897 3.9836 12.4139
SNU-761 CTRP2 4.6734 5.8663 4.5928 9.4125
Hep 3B2.1-7 CTRP2 5.0765 7.3425 3.922 4.9884
SNU-423 CTRP2 5.4876 9.5665 3.8002 10.5605
SNU-398 CTRP2 5.7262 6.6364 5.4543 3.1717
SNU-387 CTRP2 5.7664 6.6895 5.4685 3.0167
SK-HEP-1 CTRP2 5.9309 7.4328 5.2535 3.5502
JHH-1 CTRP2 5.9551 11.1572 3.4132 11.2045
HLF CTRP2 5.9717 9.3256 4.3428 7.2933
JHH-4 CTRP2 6.2944 13.8429 2.3515 14.7789
Li-7 CTRP2 6.6129 19.829 -0.3801 23.0283
SNU-878 CTRP2 7.1324 10.1027 4.8346 3.3288
JHH-6 CTRP2 7.474 8.2468 5.7976 0.0399
JHH-2 CTRP2 8.0039 13.6412 3.7288 6.5145
PLC/PRF/5 CTRP2 8.1496 13.5135 3.8848 5.7129
SNU-475 CTRP2 8.2496 10.0118 5.4632 0.3313
HuH-1 CTRP2 10.0414 62.2355 -18.7936 38.2184
SNU-449 CTRP2 11.0572 21.1122 2.1649 8.4139
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 171 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1436 GDSC1 0.2275 9.227 -3.7738 32.4501
NCI-H1703 CTRP2 0.2355 9.0379 -1.3055 41.7657
DMS 79 GDSC1 1.5105 3.7566 0.0205 6.0578
NCI-H720 GDSC1 1.7896 3.1054 0.5097 1.7746
NCI-H64 GDSC1 2.0063 3.3044 0.539 1.2354
NCI-H2171 GDSC1 2.0574 11.8285 -3.5602 25.4975
NCI-H1770 GDSC1 2.123 7.9067 -1.568 15.519
NCI-H345 GDSC1 2.2616 3.125 0.7198 0.1943
LC-2/ad GDSC1 2.321 4.6733 0.1124 3.4174
NCI-H82 GDSC1 2.4893 4.3542 0.3413 1.6925
NCI-H187 GDSC1 2.634 3.826 0.6108 0.3257
LB647-SCLC GDSC1 2.6605 4.7516 0.2606 1.9148
Ms-1 GDSC1 2.7206 4.2948 0.4717 0.7764
NCI-H2141 GDSC1 2.7439 4.7018 0.3215 1.4716
IST-SL2 GDSC1 2.8304 7.1728 -0.727 8.0726
NCI-H2081 GDSC1 2.8535 4.5329 0.4371 0.8099
NCI-H1836 GDSC1 2.948 4.2566 0.576 0.2775
NCI-H1304 GDSC1 3.0302 4.7859 0.4152 0.7577
SBC-1 GDSC1 3.0328 5.26 0.2314 1.5992
NCI-H1876 GDSC1 3.0869 4.733 0.4579 0.5607
NCI-H209 GDSC1 3.1434 5.4325 0.2133 1.5656
NCI-H510A GDSC1 3.1497 10.3807 -2.0422 15.3933
NCI-H1975 GDSC1 3.1626 5.3045 0.2727 1.2579
NCI-H748 GDSC1 3.1915 5.0709 0.3748 0.7944
NCI-H847 GDSC1 3.2171 4.5049 0.5871 0.1649
Lu-139 GDSC1 3.2429 5.3472 0.2912 1.0986
IST-SL1 GDSC1 3.2756 6.5241 -0.1754 3.5743
HCC33 GDSC1 3.2846 5.0376 0.4245 0.5535
Lu-165 GDSC1 3.3032 4.8554 0.4969 0.3326
NCI-H322M GDSC1 3.4228 6.6292 -0.144 3.1601
NCI-H524 GDSC1 3.555 12.4803 -2.7756 18.0541
NCI-H1963 GDSC1 3.5775 5.3441 0.4266 0.3992
Lu-134-A GDSC1 3.6361 7.4825 -0.3975 4.3337
NCI-H1648 GDSC1 3.8175 5.7118 0.3862 0.4027
NCI-H2135 GDSC1 3.8702 5.5118 0.4742 0.1983
CPC-N GDSC1 3.9582 5.6627 0.4538 0.2117
EBC-1 CTRP2 4.0687 5.9619 3.9102 13.7145
NCI-H211 GDSC1; CTRP2 4.3561 7.4103 3.7083 13.654
NCI-H2106 CTRP2 4.5549 5.7592 4.4869 10.1568
NCI-H1666 GDSC1; CTRP2 4.6218 5.8346 4.5437 9.7469
SW1271 CTRP2 4.6594 6.891 4.2399 10.7678
NCI-H1435 CTRP2 4.738 7.8228 3.9217 11.812
Calu-3 CTRP2 4.7581 6.7836 4.3871 9.9289
HCC1588 CTRP2 4.7766 5.8841 4.7011 8.707
NCI-H446 GDSC1; CTRP2 4.8089 5.6822 4.7749 8.3469
NCI-H2342 CTRP2 4.8212 9.4734 3.2279 14.4114
NCI-H69 GDSC1; CTRP2 4.8371 10.5794 2.7061 16.462
COR-L51 CTRP2 4.881 8.2205 3.8814 11.6172
NCI-H2087 CTRP2 4.8902 6.2381 4.727 8.2691
NCI-H1693 CTRP2 4.903 8.7315 3.6618 12.4558
NCI-H1568 CTRP2 4.9304 9.0577 3.532 12.9197
NCI-H2122 CTRP2 5.0021 6.2339 4.8501 7.4845
NCI-H2405 CTRP2 5.0514 8.6852 3.2298 8.1547
NCI-H810 CTRP2 5.0549 8.9219 3.716 11.8765
SK-MES-1 CTRP2 5.0585 7.6554 4.3197 9.4075
NCI-H1573 CTRP2 5.0779 6.2508 4.9268 6.9778
NCI-H1341 CTRP2 5.0856 8.2802 4.0531 10.4248
NCI-H2196 GDSC1; CTRP2 5.1242 10.9668 2.7797 15.5201
NCI-H1155 GDSC1; CTRP2 5.1392 6.1526 5.025 6.4343
NCI-H520 CTRP2 5.1756 6.2819 5.0222 6.3379
NCI-H2110 CTRP2 5.2241 8.8145 3.9278 10.6161
NCI-H1623 CTRP2 5.2387 11.9566 2.3926 16.7846
NCI-H2228 CTRP2 5.2438 6.2861 5.0945 5.8698
NCI-H1373 CTRP2 5.2481 6.3231 5.086 5.8893
LCLC-97TM1 CTRP2 5.2761 6.5512 5.0285 6.0304
COLO 668 GDSC1; CTRP2 5.2916 7.5336 4.6068 7.6723
LXF 289 GDSC1; CTRP2 5.2941 7.6125 4.5722 7.8067
NCI-H1838 GDSC1; CTRP2 5.3088 6.2843 5.1653 5.417
NCI-H1944 CTRP2 5.3464 11.6433 2.6439 15.5712
NCI-H292 CTRP2 5.3798 6.8208 5.0219 5.7805
DV-90 CTRP2 5.3884 7.0014 4.9494 6.0482
HCC2279 CTRP2 5.4 6.3937 5.2224 4.9426
NCI-H1581 GDSC1; CTRP2 5.4093 7.255 4.853 6.3855
DMS 454 CTRP2 5.4134 6.4261 5.2239 4.8993
NCI-H2029 CTRP2 5.4181 7.1048 4.9316 6.0455
HCC44 CTRP2 5.424 6.536 5.1902 5.001
NCI-H1792 CTRP2 5.4407 6.9479 5.0264 5.6073
DMS 114 GDSC1; CTRP2 5.4523 6.428 5.2643 4.6366
NCI-H23 GDSC1; CTRP2 5.457 6.6342 5.1828 4.9423
LC-1F CTRP2 5.4714 9.3184 3.9084 10.1462
COR-L95 GDSC1; CTRP2 5.4835 8.3271 4.4075 8.0453
COLO 699 CTRP2 5.4837 7.3759 4.2214 2.8905
NCI-H1915 CTRP2 5.489 12.7999 2.1933 17.0066
NCI-H1105 CTRP2 5.4904 9.0564 4.055 9.4953
NCI-H522 CTRP2 5.492 9.919 3.6295 11.2595
NCI-H661 CTRP2 5.4924 8.2937 4.4321 7.9233
NCI-H841 CTRP2 5.5092 14.2638 1.4806 19.5492
NCI-H1092 GDSC1; CTRP2 5.5266 8.7418 4.2431 8.6336
NCI-H647 CTRP2 5.5348 6.5972 5.279 4.3584
LK2 CTRP2 5.5351 5.9329 5.5146 3.4631
RERF-LC-Ad2 CTRP2 5.5578 6.0353 5.5158 3.3883
NCI-H2444 CTRP2 5.5739 6.2467 5.4643 3.5319
NCI-H727 CTRP2 5.6062 9.5231 3.9276 9.7777
VMRC-LCD CTRP2 5.6081 6.1722 5.5281 3.1935
HCC1438 CTRP2 5.6091 6.2299 5.5084 3.2652
HCC4006 CTRP2 5.6105 6.2235 5.5122 3.2468
RERF-LC-A1 CTRP2 5.6522 7.5603 4.939 5.4631
HOP-62 GDSC1; CTRP2 5.6566 6.3313 5.5189 3.0932
HCC2935 CTRP2 5.6618 6.5767 5.4175 3.4805
LC-1/sq-SF CTRP2 5.679 6.3105 5.551 2.9076
LOU-NH91 CTRP2 5.6857 6.2547 5.5806 2.7752
Sq-1 CTRP2 5.6937 6.3992 5.5289 2.9551
T3M-10 CTRP2 5.697 6.5056 5.4852 3.1203
RERF-LC-MS CTRP2 5.7001 6.9004 5.304 3.8475
NCI-H2170 CTRP2 5.7068 11.3483 3.1061 12.9618
NCI-H889 CTRP2 5.7087 6.9792 5.2745 3.9482
HARA [Human squamous cell lung carcinoma] CTRP2 5.7153 6.4425 5.532 2.8862
NCI-H2172 CTRP2 5.7323 6.9033 5.3335 3.6506
HCC15 CTRP2 5.7393 6.7929 5.3931 3.3897
EPLC-272H CTRP2 5.7494 6.5146 5.5338 2.7931
NCI-H322 CTRP2 5.7548 12.1503 2.7469 14.3067
Lu-65 GDSC1; CTRP2 5.7738 6.5952 5.5203 2.7876
ChaGo-K-1 CTRP2 5.776 7.0415 5.3076 3.6572
NCI-H1869 GDSC1; CTRP2 5.784 10.3639 3.664 10.5082
LUDLU-1 CTRP2 5.8046 10.0184 3.8542 9.6737
CAL-12T CTRP2 5.8233 6.6498 5.5422 2.5803
NCI-H1355 GDSC1; CTRP2 5.8591 7.5728 5.1208 4.2554
NCI-H358 CTRP2 5.8647 6.8295 5.4936 2.687
NCI-H838 CTRP2 5.8928 7.4843 5.1945 3.8762
NCI-H1650 CTRP2 5.9123 7.0249 5.4401 2.8069
NCI-H1395 CTRP2 5.9145 8.2375 4.8378 5.3281
NCI-H196 CTRP2 5.9205 6.5639 5.6753 1.8082
Lu-99 CTRP2 5.9241 6.6361 5.6432 1.9339
LCLC-103H CTRP2 5.9768 7.9261 4.2866 1.8982
NCI-H1694 GDSC1; CTRP2 5.9824 13.9911 2.0192 16.6406
NCI-H441 CTRP2 6.0387 6.9884 5.5676 2.0151
PC-14 CTRP2 6.0878 8.7405 4.7323 5.4319
HCC1833 CTRP2 6.0979 7.3974 5.412 2.5568
HCC1171 CTRP2 6.1202 7.33 5.4636 2.2988
KNS-62 CTRP2 6.1334 7.1115 5.5831 1.7741
EKVX GDSC1; CTRP2 6.136 7.9398 5.1719 3.4943
Calu-1 CTRP2 6.1402 7.1119 5.5882 1.7403
Calu-6 GDSC1; CTRP2 6.177 10.2069 4.0726 8.0327
NCI-H1563 CTRP2 6.247 8.4832 4.9894 4.0584
IA-LM GDSC1; CTRP2 6.296 7.8055 5.3637 2.4106
NCI-H2286 CTRP2 6.3723 7.851 5.3976 2.1475
COR-L88 GDSC1; CTRP2 6.4034 8.7228 4.9913 3.7802
HOP-92 CTRP2 6.491 14.0812 2.3919 14.2515
SBC-5 CTRP2 6.5268 8.1209 5.3755 2.0058
NCI-H1385 CTRP2 6.5944 11.6634 3.6791 8.9122
NCI-H226 GDSC1; CTRP2 6.7326 8.9045 5.1393 2.6631
A-549 CTRP2 6.7855 8.7282 5.2584 2.1171
RERF-LC-Ad1 CTRP2 6.8004 7.7127 5.7243 0.4151
HCC95 CTRP2 7.1401 9.4883 5.1273 2.1825
NCI-H128 GDSC1 7.2599 21.0688 -4.4212 16.9618
BEN CTRP2 7.3536 8.7391 5.569 0.4963
NCI-H460 CTRP2 7.4981 10.572 4.8468 2.8231
SHP-77 GDSC1; CTRP2 7.5071 12.8883 3.7515 7.1346
MOR/CPR CTRP2 7.5268 8.5143 5.7247 0.1086
NCI-H2126 CTRP2 7.5531 9.2673 5.4492 0.7019
NCI-H526 GDSC1; CTRP2 7.5919 9.1497 5.5141 0.5045
HCC1195 CTRP2 7.6659 9.0781 5.5736 0.3304
DMS 273 CTRP2 7.717 12.0056 4.3159 4.5978
HCC827 CTRP2 7.7276 11.6433 4.4925 3.8992
SK-LU-1 CTRP2 7.7621 10.21 5.1589 1.4393
NCI-H650 CTRP2 7.8714 41.9972 -11.1321 34.9132
NCI-H2291 CTRP2 7.9596 10.3054 5.2191 1.0943
NCI-H1184 CTRP2 8.0357 9.8957 5.4183 0.5126
NCI-H1755 CTRP2 8.1417 9.7067 5.5322 0.2433
NCI-H2023 CTRP2 8.1487 9.8457 5.4841 0.3268
NCI-H1793 CTRP2 8.1756 9.6421 5.5682 0.1789
NCI-H2030 CTRP2 8.2079 9.8212 5.5164 0.2504
NCI-H1734 CTRP2 8.2094 10.6483 5.1988 0.9832
HCC366 CTRP2 8.2597 10.341 5.3432 0.5812
HCC2108 CTRP2 8.2841 11.6397 4.8191 2.1121
HCC78 CTRP2 8.3182 10.3424 5.3676 0.4992
NCI-H1299 GDSC1; CTRP2 8.3485 10.0679 5.4817 0.2674
NCI-H2009 CTRP2 8.557 10.0381 5.5691 0.1067
COR-L105 CTRP2 9.1555 14.573 4.0089 4.0849
NCI-H1339 CTRP2 11.7165 23.8627 1.3015 10.4176
Hs 888.Lu CTRP2 5.476 11.9985 2.5813 15.5402
⏷ Show the Full List of 171 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 3.2969 5.4207 0.2861 1.073
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 4.4852 14.1863 0.6108 24.6729
ES-2 GDSC1 3.6352 13.1944 -3.0652 19.1568
COV434 CTRP2 4.6744 6.9414 4.2356 10.743
SNU-119 CTRP2 4.7414 6.7438 4.3849 9.9837
TYK-nu CTRP2 4.8664 5.9792 4.776 8.1624
TOV-112D CTRP2 4.9711 8.1222 4.0162 10.8508
OAW28 CTRP2 5.0683 7.8786 4.2257 9.7635
MCAS CTRP2 5.1711 6.3495 4.9935 6.4584
OVSAHO CTRP2 5.275 6.4309 4.5327 1.8692
COV362 CTRP2 5.3004 21.6359 -2.3797 30.0891
A2780 CTRP2 5.3594 6.4173 5.1699 5.2565
OVCAR-5 CTRP2 5.3952 7.4632 4.7412 6.8748
OC 314 CTRP2 5.4035 5.9347 5.3715 4.3798
IGROV-1 CTRP2 5.4375 6.7065 5.1313 5.1969
DOV13 CTRP2 5.4661 7.4573 4.1688 3.1523
COV644 CTRP2 5.4773 6.2593 5.3559 4.2165
OAW42 CTRP2 5.5254 5.9606 5.4985 3.55
JHOS-2 CTRP2 5.5502 5.972 5.523 3.386
OVCAR-4 GDSC1; CTRP2 5.558 6.7448 5.2367 4.4675
OV-90 CTRP2 5.5628 10.4352 3.4357 11.9105
OVCAR-8 CTRP2 5.5846 6.8207 5.2285 4.4342
FU-OV-1 CTRP2 5.6801 6.5997 5.4254 3.4024
EFO-27 CTRP2 5.7805 12.5616 2.5634 14.9772
ES2 CTRP2 5.8189 7.1763 4.5337 1.1074
OVISE CTRP2 5.8536 8.1786 4.0896 2.8864
JHOM-1 CTRP2 5.938 6.8448 5.5525 2.2827
SNU-840 CTRP2 6.0638 7.2445 5.4604 2.4174
Kuramochi GDSC1; CTRP2 7.2198 11.8796 4.0389 6.4068
OV7 CTRP2 7.3963 13.0897 3.575 8.012
EFO-21 CTRP2 7.4852 14.6874 2.8569 10.7165
OV56 CTRP2 7.7575 8.9503 5.6567 0.1509
HEY A8 CTRP2 7.8294 9.663 5.4182 0.6191
TOV-21G CTRP2 7.8372 10.1865 5.2077 1.221
ONCO-DG-1 CTRP2 7.8964 9.2936 5.5866 0.2241
SNU-8 CTRP2 7.9858 9.037 5.7087 0.0546
SK-OV-3 CTRP2 8.0931 10.2491 5.3052 0.764
OVTOKO CTRP2 8.1981 10.804 5.1296 1.191
JHOC-5 CTRP2 8.23 10.3938 5.3097 0.6769
RMG-I CTRP2 8.3299 10.3143 5.3832 0.4608
Caov-3 CTRP2 8.4207 10.8472 5.2165 0.8092
OVK18 CTRP2 8.4369 10.166 5.4803 0.2449
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 5.1837 6.3729 4.9986 6.4028
Yamato-SS CTRP2 5.6759 6.7064 5.372 3.6285
A-204 CTRP2 1.0591 9.1443 -0.4719 37.282
SW684 GDSC1 1.73 12.8442 -4.3253 29.0697
G-402 CTRP2 1.7418 9.4493 0.1226 33.5965
SW872 GDSC1 2.0585 4.2782 0.1365 3.7949
MFH-ino GDSC1 3.2286 5.2448 0.3244 0.9687
VA-ES-BJ GDSC1 3.2315 5.2616 0.3192 0.9881
EW-8 GDSC1 3.2674 4.8985 0.4681 0.4276
Rh41 CTRP2 4.4554 9.5763 2.8267 16.8917
Rh18 CTRP2 4.5759 5.3094 4.5678 9.8103
GCT CTRP2 5.0561 5.9188 4.9973 6.7874
RD CTRP2 5.3182 8.7091 4.0672 9.8268
G-401 CTRP2 5.3339 9.3465 3.7694 11.0236
KYM-1 GDSC1; CTRP2 5.3767 5.9152 5.3464 4.5523
Hs 729.T CTRP2 5.4057 11.5977 2.719 15.1475
TE 617.T CTRP2 5.4168 6.1569 5.3257 4.5051
TE 441.T GDSC1; CTRP2 5.4388 13.0987 2.0007 17.8337
HT-1080 CTRP2 5.5453 6.1524 5.4668 3.6053
SK-UT-1 GDSC1; CTRP2 5.5522 6.3537 5.3998 3.8394
MES-SA CTRP2 5.8161 6.4337 5.6375 2.2086
Tm87-16 CTRP2 5.9137 7.1583 5.3751 3.0761
TTC-709 CTRP2 6.0227 8.1634 4.9668 4.5717
SW982 GDSC1; CTRP2 6.3762 7.8129 5.4191 2.0528
RKN CTRP2 6.5393 10.049 4.4381 5.8541
BT-12 CTRP2 6.6896 8.2319 5.4302 1.5695
BT-16 CTRP2 7.402 8.7493 5.5868 0.4235
SK-LMS-1 GDSC1; CTRP2 8.1055 10.4495 5.2304 0.9614
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 5.6699 6.1536 5.6014 2.741
SYO-1 CTRP2 6.6971 12.5937 3.2966 10.2981
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 5.9119 6.743 5.5794 4.7826
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1 4.3354 6.171 0.4133 0.1909
NCI-H2452 CTRP2 5.4234 8.3303 4.3501 8.4184
JL-1 CTRP2 5.5931 5.9371 5.5765 3.0631
NCI-H2052 CTRP2 5.8264 7.0922 5.3293 3.4546
MPP 89 GDSC1; CTRP2 5.9833 7.0187 5.5055 2.386
ACC-MESO-1 CTRP2 7.8697 9.5202 5.4914 0.4223
NCI-H28 CTRP2 8.088 10.8112 5.0716 1.452
IST-Mes1 GDSC1; CTRP2 8.1187 16.7278 2.3172 11.7565
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VCaP GDSC1; CTRP2 4.8676 5.66 4.841 7.9302
LNCaP clone FGC GDSC1; CTRP2 5.2016 9.7746 3.4375 12.6853
22Rv1 CTRP2 5.2544 8.048 3.7138 5.5717
DU145 CTRP2 7.101 11.7487 4.0177 6.6761
PaCa-3 CTRP2 7.1029 10.7014 4.5281 4.5965
NCI-H660 CTRP2 7.9594 9.0888 5.6819 0.0816
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; CTRP2 6.0711 7.7778 5.1998 3.4991
YD-15 CTRP2 8.1537 9.3479 5.6621 0.0739
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 3.3849 4.9149 0.5061 0.2788
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RF-48 GDSC1 2.6837 4.3465 0.4356 0.971
HSC-39 GDSC1 2.8146 4.8409 0.2984 1.5082
GCIY GDSC1 3.5475 5.2831 0.4369 0.385
Fu97 CTRP2 3.5842 12.7182 0.4868 27.2661
GSS CTRP2 3.6739 4.9796 3.6523 15.8652
SNU-1 GDSC1; CTRP2 3.9262 8.7872 2.6658 18.8571
ECC10 CTRP2 4.6245 5.18 4.6227 9.4655
SNU-16 GDSC1; CTRP2 4.6756 7.5749 3.9686 11.7854
IM95 CTRP2 5.2367 6.1839 5.1212 5.7916
SNU-601 CTRP2 5.3149 6.5116 5.0854 5.7047
MKN74 CTRP2 5.4623 7.0681 4.9925 5.6904
Hs 746.T CTRP2 5.5077 6.2256 5.4008 3.9605
KATO III CTRP2 5.5988 6.65 5.3208 4.0276
SNU-216 CTRP2 5.7164 6.7018 5.414 3.3594
NUGC-4 CTRP2 5.728 6.4836 5.5265 2.8763
MKN45 CTRP2 5.9298 7.7109 4.3568 1.6736
SH-10-TC CTRP2 6.0671 6.8967 5.637 1.669
KE-39 CTRP2 6.1991 8.7126 4.8369 4.7848
HGC-27 CTRP2 6.2347 10.0984 4.1738 7.5011
MKN1 CTRP2 6.4283 8.6763 5.0331 3.5647
MKN7 CTRP2 6.7367 11.3555 3.9415 7.5819
GSU CTRP2 6.9278 7.5069 5.8571 0.0605
LMSU CTRP2 7.0109 18.1243 0.7898 18.8889
SNU-5 GDSC1; CTRP2 7.5716 9.1117 5.52 0.5006
ECC12 CTRP2 7.6364 8.7751 5.6733 0.1564
SNU-668 CTRP2 7.6461 9.7949 5.2758 1.1576
NUGC-3 CTRP2 7.6614 10.2274 5.0972 1.7387
SNU-620 CTRP2 7.7116 9.2459 5.529 0.4087
AGS CTRP2 7.7605 11.023 4.7981 2.7074
SNU-719 CTRP2 8.0167 10.0886 5.3343 0.7315
NCI-N87 CTRP2 8.0717 10.491 5.1971 1.0802
23132/87 CTRP2 8.5884 9.939 5.6134 0.0648
HuG1-N CTRP2 9.2803 21.8306 0.6585 15.5755
SNG-M CTRP2 5.3484 6.4875 5.1306 5.438
SNU-685 CTRP2 5.4693 11.8233 2.6627 15.2346
SNU-1077 CTRP2 7.1397 11.3348 4.2471 5.6817
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 1.3433 18.7115 -4.5343 41.8121
TT2609-C02 CTRP2 2.7978 7.0226 2.1931 23.7732
K5 GDSC1 3.2554 4.9642 0.4398 0.5207
CGTH-W-1 GDSC1; CTRP2 3.3267 14.2622 -0.5025 30.5638
TT CTRP2 4.9834 5.9248 4.9169 7.2986
8505C CTRP2 5.1976 6.2293 5.0639 6.1183
CAL-62 CTRP2 5.5267 6.2601 5.4087 3.8764
ML-1 [Human leukemia] CTRP2 5.7186 6.4402 5.5364 2.8607
BHT-101 CTRP2 8.0144 9.6976 5.4847 0.3758
B-CPAP CTRP2 8.0551 9.3325 5.6323 0.12
8305C CTRP2 8.2408 9.6254 5.598 0.1267
FTC-133 CTRP2 8.7852 17.9321 2.2006 11.183
FTC-238 CTRP2 13.8158 35.6252 -2.8787 18.5445
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BB49-HNC GDSC1 1.3237 5.1137 -0.7937 12.8443
SCC-15 GDSC1 2.2131 5.7625 -0.462 7.7388
BB30-HNC GDSC1 3.3841 4.972 0.4858 0.3276
LB771-HNC GDSC1 3.8917 5.8626 0.3606 0.4376
Detroit 562 CTRP2 3.9357 5.5376 3.6713 8.9424
SCC-25 CTRP2 4.6174 5.9789 4.5045 9.8999
HSC-3 CTRP2 4.7279 5.5564 4.493 3.2258
CAL-33 CTRP2 4.8301 6.5889 4.5389 9.1475
BICR 22 CTRP2 5.3292 6.2229 5.2087 5.1956
YD-8 CTRP2 5.3379 6.5303 5.1022 5.5764
BICR 18 CTRP2 5.3806 12.0894 2.4523 16.2466
PE/CA-PJ49 CTRP2 5.6189 6.1814 5.5366 3.1308
BICR 6 CTRP2 5.737 6.2284 5.6454 2.3838
PE/CA-PJ15 CTRP2 5.8303 7.2504 5.2548 3.7568
BICR 31 CTRP2 5.9135 6.983 5.462 2.7128
PE/CA-PJ34 (clone C12) CTRP2 5.9443 8.6844 4.6401 6.099
BICR 16 CTRP2 5.9681 9.1612 4.422 6.9681
PE/CA-PJ41 (clone D2) CTRP2 5.9699 15.121 1.4439 18.7235
SNU-1066 CTRP2 5.9758 7.6365 4.4176 1.3804
FaDu CTRP2 6.026 6.8061 5.6481 1.7016
HSC-4 CTRP2 6.1947 7.5106 5.4325 2.2962
SNU-1041 CTRP2 6.6861 8.2033 4.5344 0.4374
HSC-2 CTRP2 6.7092 12.5345 3.3354 10.1188
BICR 56 CTRP2 7.4169 8.6227 5.642 0.2881
YD-10B CTRP2 7.5394 9.1603 5.486 0.6085
SNU-899 CTRP2 7.9545 9.7882 5.4247 0.5369
SNU-1076 CTRP2 7.998 9.0594 5.7054 0.0559
SNU-46 CTRP2 8.0363 13.9317 3.6118 6.9273
SCC-4 CTRP2 8.0983 9.9776 5.4136 0.4942
BHY CTRP2 8.1188 10.4539 5.2348 0.9402
SNU-1214 CTRP2 8.4673 10.6053 5.3304 0.5163
SCC-9 CTRP2 9.1326 17.731 2.531 9.5087
CAL-27 CTRP2 14.1291 39.8816 -4.7028 21.5581
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
253J-BV CTRP2 5.096 7.9851 4.2029 9.7887
CAL-29 CTRP2 5.13 6.2074 4.9977 6.5623
U-BLC1 CTRP2 5.1702 8.8932 3.839 11.1051
RT-112 CTRP2 5.1823 6.2505 5.0402 6.2511
TCCSUP CTRP2 5.3164 6.1113 5.2306 5.1526
SW1710 CTRP2 5.5874 7.9594 4.6837 6.6674
J82 CTRP2 5.7671 9.3307 4.1648 8.4513
BC-3C CTRP2 5.7823 6.4094 5.6147 2.3851
HT-1197 CTRP2 5.8488 7.2208 5.2861 3.5861
5637 CTRP2 6.0869 7.9915 5.106 3.863
VM-CUB-1 CTRP2 6.1107 9.174 4.5345 6.2194
UM-UC-3 CTRP2 7.0616 9.5477 5.0505 2.5738
639V CTRP2 7.544 9.1759 5.4818 0.617
253J CTRP2 7.6026 9.6018 5.3351 1.0054
HT-1376 CTRP2 7.6947 10.9407 4.7965 2.7861
KU-19-19 CTRP2 7.7274 9.1415 5.5752 0.3027
RT-4 CTRP2 7.7687 11.0764 4.7787 2.7697
JMSU-1 CTRP2 7.8922 9.418 5.5392 0.3126
UM-UC-1 CTRP2 7.9629 14.7664 3.1603 8.7957
T24 CTRP2 8.4399 14.9365 3.4013 7.1932
KMBC-2 CTRP2 8.532 14.3764 3.724 5.8428
647V CTRP2 13.2968 46.556 -8.5312 27.7521
SCaBER CTRP2 13.6241 32.7637 -1.6499 16.1195
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCC-IT GDSC1 2.4803 4.6569 0.208 2.506
SW962 GDSC1 2.8453 4.8531 0.3079 1.4233
JAR GDSC1 3.0339 4.4688 0.533 0.3546
DSH1 GDSC1 3.3181 5.5122 0.26 1.168
NT2-D1 GDSC1 3.3244 12.0951 -2.7501 18.5219
OMC-1 [Human cervical carcinoma] GDSC1 3.3597 5.192 0.3977 0.5977
SW954 GDSC1 3.4093 5.2395 0.3999 0.5618
LB831-BLC GDSC1 3.6089 5.6336 0.3345 0.6595
NEC8 GDSC1 4.1319 19.6903 -5.8809 27.2272
KGN GDSC1 4.5492 6.3173 0.4373 0.1215
HeLa CTRP2 6.1356 7.7902 5.2463 3.1826
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Imatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Imatinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Nilotinib DM7HXWT Moderate Decreased metabolism of Imatinib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [36]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Imatinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Dasatinib DMJV2EK Moderate Decreased metabolism of Imatinib caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [38]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Imatinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [39]
Coadministration of a Drug Treating the Disease Different from Imatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [40]
Tretinoin DM49DUI Moderate Decreased metabolism of Imatinib caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [41]
Metreleptin DM1NOEK Moderate Increased metabolism of Imatinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [42]
Repaglinide DM5SXUV Moderate Decreased metabolism of Imatinib caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [43]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Imatinib caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [35]
Nateglinide DMLK2QH Moderate Decreased metabolism of Imatinib caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [44]
Ivosidenib DM8S6T7 Major Increased metabolism of Imatinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [45]
Midostaurin DMI6E0R Moderate Decreased metabolism of Imatinib caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Arn-509 DMT81LZ Major Increased metabolism of Imatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [42]
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Imatinib caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Oliceridine DM6MDCF Major Decreased metabolism of Imatinib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [47]
Mitotane DMU1GX0 Major Increased metabolism of Imatinib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [42]
Donepezil DMIYG7Z Minor Decreased metabolism of Imatinib caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [48]
Ivabradine DM0L594 Major Decreased metabolism of Imatinib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [37]
Bepridil DM0RKS4 Moderate Decreased metabolism of Imatinib caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [35]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Imatinib caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [49]
Nifedipine DMSVOZT Moderate Decreased metabolism of Imatinib caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [50]
Clorazepate DMC3JST Moderate Decreased metabolism of Imatinib caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [40]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Imatinib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [42]
Posaconazole DMUL5EW Moderate Decreased metabolism of Imatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [35]
Budesonide DMJIBAW Moderate Decreased metabolism of Imatinib caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [51]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Imatinib and Roflumilast. Asthma [CA23] [37]
Zileuton DMVRIC2 Moderate Decreased metabolism of Imatinib caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [35]
Oritavancin DM28D05 Moderate Increased metabolism of Imatinib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Imatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [40]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Imatinib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Imatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Imatinib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [52]
Ag-221 DMS0ZBI Moderate Decreased clearance of Imatinib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [40]
Cariprazine DMJYDVK Moderate Decreased metabolism of Imatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [53]
Erdafitinib DMI782S Moderate Decreased clearance of Imatinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [54]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Imatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [55]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Imatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Imatinib caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
HKI-272 DM6QOVN Major Decreased metabolism of Imatinib caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
LY2835219 DM93VBZ Moderate Decreased metabolism of Imatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Imatinib caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Tucatinib DMBESUA Moderate Decreased metabolism of Imatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Imatinib caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Imatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Bosutinib DMTI8YE Major Decreased metabolism of Imatinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Estradiol DMUNTE3 Moderate Decreased metabolism of Imatinib caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Atorvastatin DMF28YC Moderate Decreased metabolism of Imatinib caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [61]
Macitentan DMP79A1 Moderate Decreased metabolism of Imatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [62]
PF-04449913 DMSB068 Moderate Decreased metabolism of Imatinib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [63]
Indacaterol DMQJHR7 Minor Decreased metabolism of Imatinib caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [64]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Imatinib caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [42]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Imatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [40]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Imatinib caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [65]
Ulipristal DMBNI20 Minor Decreased metabolism of Imatinib caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [37]
Mestranol DMG3F94 Moderate Decreased metabolism of Imatinib caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [40]
Levobupivacaine DM783CH Moderate Decreased metabolism of Imatinib caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Cocaine DMSOX7I Moderate Decreased metabolism of Imatinib caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [40]
Alfentanil DMVO0UB Major Decreased metabolism of Imatinib caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [66]
Mifepristone DMGZQEF Moderate Decreased metabolism of Imatinib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [67]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Imatinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [37]
Ivacaftor DMZC1HS Major Decreased metabolism of Imatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [37]
MK-8228 DMOB58Q Moderate Decreased metabolism of Imatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [35]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Imatinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [40]
Aprepitant DM053KT Moderate Decreased metabolism of Imatinib caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Sertraline DM0FB1J Moderate Decreased metabolism of Imatinib caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Trimipramine DM1SC8M Moderate Decreased metabolism of Imatinib caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Vilazodone DM4LECQ Moderate Decreased metabolism of Imatinib caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Paroxetine DM5PVQE Moderate Decreased metabolism of Imatinib caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Escitalopram DMFK9HG Minor Decreased metabolism of Imatinib caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Desvenlafaxine DMHD4PE Moderate Decreased metabolism of Imatinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
OPC-34712 DMHG57U Major Decreased metabolism of Imatinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [71]
Clomipramine DMINRKW Moderate Decreased metabolism of Imatinib caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Trazodone DMK1GBJ Moderate Decreased metabolism of Imatinib caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Doxepin DMPI98T Moderate Decreased metabolism of Imatinib caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Imatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [72]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Imatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [40]
Ospemifene DMC4GEI Moderate Decreased metabolism of Imatinib caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [73]
Diazepam DM08E9O Moderate Decreased metabolism of Imatinib caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Imatinib caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Primidone DM0WX6I Major Increased metabolism of Imatinib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Felbamate DM1V5ZS Moderate Increased metabolism of Imatinib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Imatinib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Cenobamate DM8KLU9 Moderate Increased metabolism of Imatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Imatinib caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Stiripentol DMMSDOY Moderate Decreased metabolism of Imatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Fosphenytoin DMOX3LB Major Increased metabolism of Imatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Clonazepam DMTO13J Moderate Decreased metabolism of Imatinib caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Lacosamide DMVM6QR Moderate Decreased metabolism of Imatinib caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Rufinamide DMWE60C Moderate Increased metabolism of Imatinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Phenobarbital DMXZOCG Major Increased metabolism of Imatinib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Imatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Cannabidiol DM0659E Minor Decreased metabolism of Imatinib caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [37]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Imatinib caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [35]
Mefenamic acid DMK7HFI Moderate Decreased metabolism of Imatinib caused by Mefenamic acid mediated inhibition of CYP450 enzyme. Female pelvic pain [GA34] [35]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Imatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [74]
Tazemetostat DMWP1BH Major Decreased metabolism of Imatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Solifenacin DMG592Q Moderate Decreased metabolism of Imatinib caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [76]
Mirabegron DMS1GYT Minor Decreased metabolism of Imatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [77]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Imatinib caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [78]
Itraconazole DMCR1MV Moderate Decreased metabolism of Imatinib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Miconazole DMPMYE8 Moderate Decreased metabolism of Imatinib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Imatinib caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [79]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Imatinib caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [80]
Ripretinib DM958QB Moderate Decreased metabolism of Imatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [40]
Avapritinib DMK2GZX Major Decreased metabolism of Imatinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Colchicine DM2POTE Major Decreased metabolism of Imatinib caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [81]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Imatinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [42]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Imatinib caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [82]
Eplerenone DMF0NQR Major Decreased metabolism of Imatinib caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [83]
Carvedilol DMHTEAO Moderate Decreased metabolism of Imatinib caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [35]
Boceprevir DMBSHMF Moderate Decreased metabolism of Imatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Telaprevir DMMRV29 Moderate Decreased metabolism of Imatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Imatinib caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [40]
Rifampin DMA8J1G Major Increased metabolism of Imatinib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [42]
Rifapentine DMCHV4I Major Increased metabolism of Imatinib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [42]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [84]
MK-1439 DM215WE Minor Decreased metabolism of Imatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Delavirdine DM3NF5G Moderate Decreased metabolism of Imatinib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Fostemsavir DM50ILT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [86]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Imatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Imatinib caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Dolutegravir DMCZGRE Minor Decreased metabolism of Imatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Saquinavir DMG814N Moderate Decreased metabolism of Imatinib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Etravirine DMGV8QU Moderate Decreased metabolism of Imatinib caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Imatinib caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Imatinib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Atazanavir DMSYRBX Moderate Decreased metabolism of Imatinib caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Maraviroc DMTL94F Moderate Decreased clearance of Imatinib due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [90]
Simvastatin DM30SGU Moderate Decreased metabolism of Imatinib caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [61]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Imatinib caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [40]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Imatinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [91]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Imatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [92]
BMS-201038 DMQTAGO Major Decreased metabolism of Imatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [40]
Aliskiren DM1BV7W Moderate Decreased clearance of Imatinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [65]
Losartan DM72JXH Moderate Decreased metabolism of Imatinib caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Nebivolol DM7F1PA Moderate Decreased metabolism of Imatinib caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Levamlodipine DM92S6N Moderate Decreased metabolism of Imatinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [65]
Verapamil DMA7PEW Moderate Decreased metabolism of Imatinib caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Pindolol DMD2NV7 Moderate Decreased metabolism of Imatinib caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Conivaptan DM1V329 Moderate Decreased metabolism of Imatinib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [93]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Imatinib caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [94]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Imatinib caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [35]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Imatinib caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [37]
Retapamulin DM9JXB7 Minor Decreased metabolism of Imatinib caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [95]
Lesinurad DMUR64T Moderate Decreased metabolism of Imatinib caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [96]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Imatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [35]
Suvorexant DM0E6S3 Major Decreased metabolism of Imatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [97]
Amobarbital DM0GQ8N Moderate Increased metabolism of Imatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [42]
Ramelteon DM7IW9J Moderate Decreased metabolism of Imatinib caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Imatinib caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Triazolam DMETYK5 Moderate Decreased metabolism of Imatinib caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Imatinib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [99]
ITI-007 DMUQ1DO Major Decreased metabolism of Imatinib caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [100]
Estazolam DMZGXUM Moderate Decreased metabolism of Imatinib caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Pemigatinib DM819JF Major Decreased metabolism of Imatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [37]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Imatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [42]
Testosterone DM7HUNW Moderate Decreased metabolism of Imatinib caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [35]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Imatinib and Denosumab. Low bone mass disorder [FB83] [101]
Crizotinib DM4F29C Moderate Decreased metabolism of Imatinib caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Brigatinib DM7W94S Major Decreased metabolism of Imatinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [40]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Imatinib and Porfimer Sodium. Lung cancer [2C25] [102]
Ceritinib DMB920Z Moderate Decreased metabolism of Imatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Imatinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Imatinib caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Osimertinib DMRJLAT Moderate Decreased metabolism of Imatinib caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [105]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Imatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
Capmatinib DMYCXKL Moderate Decreased clearance of Imatinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [107]
Selpercatinib DMZR15V Major Decreased metabolism of Imatinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Halofantrine DMOMK1V Major Decreased metabolism of Imatinib caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [108]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Imatinib caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [40]
Primaquine DMWQ16I Moderate Decreased metabolism of Imatinib caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [35]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [109]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Idelalisib. Mature B-cell leukaemia [2A82] [110]
GDC-0199 DMH0QKA Major Decreased metabolism of Imatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [40]
IPI-145 DMWA24P Moderate Decreased metabolism of Imatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
Acalabrutinib DM7GCVW Major Decreased metabolism of Imatinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [112]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Clofarabine. Mature B-cell lymphoma [2A85] [113]
Ibrutinib DMHZCPO Major Decreased metabolism of Imatinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [114]
Vemurafenib DM62UG5 Moderate Increased metabolism of Imatinib caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [42]
Selumetinib DMC7W6R Major Decreased metabolism of Imatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [115]
LGX818 DMNQXV8 Major Decreased metabolism of Imatinib caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [116]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Imatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [42]
Estrone DM5T6US Moderate Decreased metabolism of Imatinib caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [35]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Imatinib caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [40]
Danazol DML8KTN Moderate Decreased metabolism of Imatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [35]
Ubrogepant DM749I3 Moderate Decreased metabolism of Imatinib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [117]
Almogran DM7I64Z Moderate Decreased metabolism of Imatinib caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [35]
Rimegepant DMHOAUG Moderate Decreased metabolism of Imatinib caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [118]
Lasmiditan DMXLVDT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [119]
Exjade DMHPRWG Moderate Decreased metabolism of Imatinib caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [120]
Flibanserin DM70DTN Major Decreased metabolism of Imatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [121]
Midazolam DMXOELT Moderate Decreased metabolism of Imatinib caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [35]
Panobinostat DM58WKG Moderate Decreased metabolism of Imatinib caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [122]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Imatinib and Tecfidera. Multiple sclerosis [8A40] [123]
Siponimod DM2R86O Major Decreased metabolism of Imatinib caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [40]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Imatinib and Fingolimod. Multiple sclerosis [8A40] [124]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Imatinib and Ocrelizumab. Multiple sclerosis [8A40] [125]
Deflazacort DMV0RNS Major Decreased metabolism of Imatinib caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [37]
Modafinil DMYILBE Minor Decreased metabolism of Imatinib caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [40]
Promethazine DM6I5GR Moderate Decreased metabolism of Imatinib caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Netupitant DMEKAYI Moderate Decreased metabolism of Imatinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [37]
Granisetron DMIUW25 Moderate Decreased metabolism of Imatinib caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Ondansetron DMOTQ1I Moderate Decreased metabolism of Imatinib caused by Ondansetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Entrectinib DMMPTLH Major Decreased metabolism of Imatinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [40]
Sibutramine DMFJTDI Minor Decreased metabolism of Imatinib caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [126]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Imatinib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [35]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Imatinib caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [127]
S-297995 DM26IH8 Moderate Decreased metabolism of Imatinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [37]
Naproxen DMZ5RGV Moderate Decreased metabolism of Imatinib caused by Naproxen mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [35]
Olaparib DM8QB1D Major Decreased metabolism of Imatinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Imatinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [35]
Ibuprofen DM8VCBE Moderate Decreased metabolism of Imatinib caused by Ibuprofen mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [35]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Imatinib caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [40]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Imatinib caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [128]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Imatinib caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [129]
Istradefylline DM20VSK Moderate Decreased metabolism of Imatinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [35]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Imatinib caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [130]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Imatinib caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [35]
Abametapir DM2RX0I Moderate Decreased metabolism of Imatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [131]
Lefamulin DME6G97 Moderate Decreased metabolism of Imatinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [132]
Prednisone DM2HG4X Moderate Decreased metabolism of Imatinib caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [35]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Imatinib caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [35]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Imatinib caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [133]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Imatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [134]
Enzalutamide DMGL19D Major Increased metabolism of Imatinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [42]
Darolutamide DMV7YFT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [135]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Imatinib caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [136]
Silodosin DMJSBT6 Moderate Decreased metabolism of Imatinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [137]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Imatinib caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [138]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Imatinib caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [35]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Imatinib caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [35]
Axitinib DMGVH6N Moderate Decreased metabolism of Imatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [37]
Temsirolimus DMS104F Moderate Decreased metabolism of Imatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [139]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Imatinib and Canakinumab. Rheumatoid arthritis [FA20] [140]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Imatinib and Rilonacept. Rheumatoid arthritis [FA20] [140]
Dexamethasone DMMWZET Moderate Increased metabolism of Imatinib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [42]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Imatinib and Leflunomide. Rheumatoid arthritis [FA20] [92]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Imatinib caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [35]
Quetiapine DM1N62C Moderate Decreased metabolism of Imatinib caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [141]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Imatinib caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [35]
Thioridazine DM35M8J Major Decreased metabolism of Imatinib caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [142]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Imatinib caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [143]
Perphenazine DMA4MRX Moderate Decreased metabolism of Imatinib caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [35]
Risperidone DMN6DXL Moderate Decreased metabolism of Imatinib caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [35]
Fentanyl DM8WAHT Major Decreased metabolism of Imatinib caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [40]
Sufentanil DMU7YEL Moderate Decreased metabolism of Imatinib caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [35]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Imatinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [144]
Avanafil DM75CXN Major Decreased metabolism of Imatinib caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [145]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Imatinib caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [146]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Imatinib caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [147]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Imatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [35]
Tedizolid DMG2SKR Moderate Decreased clearance of Imatinib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [37]
LDE225 DMM9F25 Major Decreased metabolism of Imatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [148]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Imatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [37]
Larotrectinib DM26CQR Moderate Decreased metabolism of Imatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Methylprednisolone DM4BDON Moderate Decreased metabolism of Imatinib caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Imatinib caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Docetaxel DMDI269 Moderate Decreased metabolism of Imatinib caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [149]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [37]
Armodafinil DMGB035 Minor Decreased metabolism of Imatinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
LEE011 DMMX75K Moderate Decreased metabolism of Imatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Etoposide DMNH3PG Moderate Decreased metabolism of Imatinib caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Imatinib caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Norethindrone DMTY169 Moderate Decreased metabolism of Imatinib caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Taxol DMUOT9V Moderate Decreased metabolism of Imatinib caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [150]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Imatinib caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Imatinib caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [37]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Naltrexone. Substance abuse [6C40] [151]
Warfarin DMJYCVW Major Decreased metabolism of Imatinib caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [65]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Imatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [152]
Eltrombopag DMOGFIX Moderate Decreased clearance of Imatinib due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [153]
As-1670542 DMV05SW Major Decreased metabolism of Imatinib caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [154]
Apixaban DM89JLN Moderate Decreased metabolism of Imatinib caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [37]
Brilinta DMBR01X Moderate Decreased metabolism of Imatinib caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [37]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Imatinib caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [155]
Sirolimus DMGW1ID Moderate Decreased metabolism of Imatinib caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [35]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Imatinib and Azathioprine. Transplant rejection [NE84] [40]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Imatinib caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [35]
Tolbutamide DM02AWV Moderate Decreased metabolism of Imatinib caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [35]
Saxagliptin DMGXENV Moderate Decreased metabolism of Imatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [37]
Elagolix DMB2C0E Moderate Increased metabolism of Imatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [42]
Astemizole DM2HN6Q Moderate Decreased metabolism of Imatinib caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [35]
Triamcinolone DM98IXF Moderate Decreased metabolism of Imatinib caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [35]
Fluticasone DMGCSVF Moderate Decreased metabolism of Imatinib caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [40]
Propafenone DMPIBJK Moderate Decreased metabolism of Imatinib caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [35]
Flecainide DMSQDLE Moderate Decreased metabolism of Imatinib caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [35]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Imatinib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [35]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Imatinib and Ganciclovir. Virus infection [1A24-1D9Z] [40]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Imatinib and Valganciclovir. Virus infection [1A24-1D9Z] [40]
⏷ Show the Full List of 286 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Imatinib 100 mg tablet 100 mg Oral Tablet Oral
Imatinib 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Imatinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
5 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
6 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
7 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
8 BDDCS applied to over 900 drugs
9 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
14 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
15 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
16 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
17 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
18 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
22 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
23 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
24 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
25 Drug Interactions Flockhart Table
26 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
27 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
28 Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
29 Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
30 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
31 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
32 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
33 The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
34 Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
35 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
39 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
40 Cerner Multum, Inc. "Australian Product Information.".
41 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
42 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
43 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
44 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
45 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
46 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
47 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
48 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
49 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
50 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
51 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
52 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
53 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
54 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
55 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
56 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
57 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
58 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
59 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
60 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
61 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
62 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
63 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
65 Canadian Pharmacists Association.
66 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
67 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
68 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
69 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
70 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
71 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
72 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
73 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
74 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
75 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
76 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
77 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
78 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
79 Dutreix C, Peng B, Mehring G, et al. "Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects." Cancer Chemother Pharmacol 54 (2004): 290-4. [PMID: 15138710]
80 Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M "Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes." Eur J Clin Pharmacol 57 (2001): 709-15. [PMID: 11829200]
81 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
82 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
83 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
84 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
85 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
86 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
87 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
88 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
89 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
90 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
92 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
93 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
94 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
95 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
96 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
97 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
98 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
99 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
100 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
101 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
102 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
103 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
104 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
105 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
106 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
107 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
108 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
109 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
110 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
111 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
112 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
114 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
115 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
116 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
117 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
118 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
119 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
120 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
121 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
122 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
123 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
124 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
125 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
126 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
127 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
128 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
129 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
130 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
131 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
132 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
133 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
134 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
135 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
136 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
137 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
138 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
139 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
140 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
141 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
142 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
143 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
144 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
145 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
146 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
147 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
148 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
149 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
150 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
151 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
152 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
153 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]
154 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
155 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.